RayKnowChina Research Map
Shortlist

Cancer

Breast cancer

乳腺癌

Tumours or cancer of the breast.

Definition adapted from MeSH (US National Library of Medicine)

hospitals in mainland China
219

with a paper from 2016–2025 or a registered study

cities
68

where those hospitals are

open trials in China
754

ClinicalTrials.gov, 18 Nov 2026

Mainland China accounts for 24% of the world's English-language research papers on breast cancer, 2021–2025 (16% in 2016–2020), and 14% of the world's registered trials on it have a site in China.

Research activity in public records, not a rating of care and not medical advice. How the numbers are made

219 hospitals in 68 cities

Order: papers led on breast cancer, 2021–2025, then A–Z. Research activity, not a rating of care.

A hospital is listed when it led at least 18 papers or 1 trial on breast cancer, or was a site in 11 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions

A square is a city. Its size and number are hospitals listed for this disease, not the amount of research. Choose one to show that city in the hospital list and the trial list.

Cities with the most listed hospitals

  1. Beijing20
  2. Shanghai19
  3. Guangzhou17
  4. Hangzhou9
  5. Jinan8
  6. Xi'an8
  7. Shenzhen7
  8. Wuhan7
  9. Chongqing6
  10. Fuzhou6

Each opens breast cancer in that city. 58 more cities are in the menu below.

  1. 390 papers led
  2. 333 papers led
  3. 313 papers led
  4. Jiangsu Province Hospital

    江苏省人民医院(南医大一附院)Nanjing

    250 papers led
  5. 246 papers led
  6. 222 papers led
  7. Harbin Medical University Cancer Hospital

    哈尔滨医科大学附属肿瘤医院Harbin

    168 papers led
  8. Sun Yat-sen Memorial Hospital

    中山大学孙逸仙纪念医院Guangzhou

    135 papers led
  9. 133 papers led
    No open trial led
  10. 132 papers led
  11. First Hospital of China Medical University

    中国医科大学附属第一医院Shenyang

    130 papers led
  12. 116 papers led
    No open trial led
  13. 116 papers led
  14. Tongji Hospital

    华中科技大学同济医学院附属同济医院WuhanInternational Medical Department

    116 papers led
  15. Ruijin Hospital

    上海交通大学医学院附属瑞金医院Shanghai

    115 papers led
  16. 114 papers led
    No open trial led
  17. 110 papers led
  18. 109 papers led
  19. 106 papers led
  20. 106 papers led
  21. 97 papers led
    No open trial led
  22. 96 papers led
  23. Union Hospital

    华中科技大学同济医学院附属协和医院Wuhan

    95 papers led
  24. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    91 papers led
  25. 88 papers led
  26. Nanfang Hospital

    南方医科大学南方医院Guangzhou

    83 papers led
  27. Xiangya Hospital

    中南大学湘雅医院Changsha

    83 papers led
  28. 81 papers led
  29. 80 papers led
  30. 79 papers led
  31. 77 papers led
  32. 77 papers led
  33. Henan Cancer Hospital

    河南省肿瘤医院Zhengzhou

    77 papers led
  34. Renji Hospital

    上海交通大学医学院附属仁济医院Shanghai

    76 papers led
  35. 76 papers led
  36. 75 papers led
  37. 74 papers led
  38. 74 papers led
  39. Second Xiangya Hospital

    中南大学湘雅二医院Changsha

    72 papers led
    No open trial led
  40. Chongqing University Cancer Hospital

    重庆大学附属肿瘤医院Chongqing

    70 papers led
    No open trial led
  41. 70 papers led
    No open trial led
  42. Fujian Medical University Union Hospital

    福建医科大学附属协和医院Fuzhou

    68 papers led
  43. 68 papers led
    No open trial led
  44. 67 papers led
    No open trial led
  45. First Affiliated Hospital, Zhejiang University

    浙江大学医学院附属第一医院Hangzhou

    64 papers led
  46. Shengjing Hospital of China Medical University

    中国医科大学附属盛京医院Shenyang

    63 papers led
  47. Shanghai General Hospital

    上海市第一人民医院Shanghai

    62 papers led
    No open trial led
  48. Guangxi Medical University Cancer Hospital

    广西医科大学附属肿瘤医院Nanning

    60 papers led
    No open trial led
  49. Yunnan Cancer Hospital

    云南省肿瘤医院Kunming

    58 papers led
  50. 57 papers led
    No open trial led
  51. Sichuan Cancer Hospital

    四川省肿瘤医院Chengdu

    56 papers led
  52. 55 papers led
    No open trial led
  53. 54 papers led
  54. Hunan Cancer Hospital

    湖南省肿瘤医院Changsha

    54 papers led
  55. First Affiliated Hospital of USTC

    中国科学技术大学附属第一医院(安徽省立医院)Hefei

    52 papers led
    No open trial led
  56. China-Japan Union Hospital, Jilin University

    吉林大学白求恩第三医院(中日联谊医院)Changchun

    51 papers led
    No open trial led
  57. 50 papers led
    No open trial led
  58. 50 papers led
  59. 50 papers led
    No open trial led
  60. 49 papers led
  61. 49 papers led
  62. First Affiliated Hospital of Zhejiang Chinese Medical University

    浙江中医药大学附属第一医院(浙江省中医院)Hangzhou

    49 papers led
    No open trial led
  63. Sir Run Run Shaw Hospital

    浙江大学医学院附属邵逸夫医院Hangzhou

    49 papers led
  64. 48 papers led
    No open trial led
  65. Jiangsu Cancer Hospital

    江苏省肿瘤医院Nanjing

    47 papers led
  66. Southwest Hospital, Army Medical University

    陆军军医大学第一附属医院(西南医院)Chongqing

    47 papers led
    No open trial led
  67. Xijing Hospital

    空军军医大学西京医院Xi'an

    47 papers led
  68. Hainan General Hospital / Hainan Medical University hospitals

    海南医学院附属医院/海南省人民医院Haikou

    45 papers led
  69. Hubei Cancer Hospital

    湖北省肿瘤医院Wuhan

    45 papers led
  70. 45 papers led
    No open trial led
  71. 45 papers led
  72. 44 papers led
    No open trial led
  73. 44 papers led
  74. 44 papers led
  75. Shanghai Tenth People's Hospital

    上海市第十人民医院Shanghai

    44 papers led
    No open trial led
  76. Zhongshan Hospital, Fudan University

    复旦大学附属中山医院Shanghai

    44 papers led
  77. 43 papers led
    No open trial led
  78. 43 papers led
    No open trial led
  79. Shanghai Sixth People's Hospital

    上海市第六人民医院Shanghai

    43 papers led
    No open trial led
  80. 41 papers led
    No open trial led
  81. 41 papers led
    No open trial led
  82. Second Hospital of Dalian Medical University

    大连医科大学附属第二医院Dalian

    41 papers led
    No open trial led
  83. 40 papers led
  84. 39 papers led
    No open trial led
  85. 39 papers led
    No open trial led
  86. 39 papers led
    No open trial led
  87. Fujian Cancer Hospital

    福建省肿瘤医院Fuzhou

    38 papers led
  88. 38 papers led
    No open trial led
  89. 38 papers led
  90. 37 papers led
    No open trial led
  91. Longhua Hospital

    上海中医药大学附属龙华医院Shanghai

    36 papers led
    No open trial led
  92. 36 papers led
    No open trial led
  93. Third Xiangya Hospital

    中南大学湘雅三医院Changsha

    36 papers led
    No open trial led
  94. 35 papers led
  95. 34 papers led
    No open trial led
  96. 31 papers led
    No open trial led
  97. 30 papers led
    No open trial led
  98. 30 papers led
    No open trial led
  99. 29 papers led
  100. 29 papers led
  101. 29 papers led
    No open trial led
  102. 29 papers led
    No open trial led
  103. 28 papers led
    No open trial led
  104. 28 papers led
    No open trial led
  105. 28 papers led
    No open trial led
  106. 28 papers led
  107. 28 papers led
    No open trial led
  108. Xinhua Hospital

    上海交通大学医学院附属新华医院Shanghai

    28 papers led
    No open trial led
  109. 27 papers led
  110. Shanghai Ninth People's Hospital

    上海交通大学医学院附属第九人民医院Shanghai

    27 papers led
    No open trial led
  111. 26 papers led
    No open trial led
  112. 26 papers led
    No open trial led
  113. 26 papers led
    No open trial led
  114. 26 papers led
    No open trial led
  115. 26 papers led
  116. Jiangxi Cancer Hospital

    江西省肿瘤医院Nanchang

    26 papers led
    No open trial led
  117. 25 papers led
    No open trial led
  118. Cancer Hospital CAMS – Shenzhen

    中国医学科学院肿瘤医院深圳医院Shenzhen

    25 papers led
    No open trial led
  119. First Affiliated Hospital of Shandong First Medical University

    山东第一医科大学第一附属医院(山东省千佛山医院)Jinan

    25 papers led
    No open trial led
  120. 25 papers led
    No open trial led
  121. 25 papers led
    No open trial led
  122. Zhongda Hospital, Southeast University

    东南大学附属中大医院Nanjing

    24 papers led
    No open trial led
  123. Zhujiang Hospital

    南方医科大学珠江医院Guangzhou

    24 papers led
    No open trial led
  124. 23 papers led
  125. 23 papers led
    No open trial led
  126. 23 papers led
    No open trial led
  127. 23 papers led
    No open trial led
  128. Xiang'an Hospital, Xiamen University

    厦门大学附属翔安医院Xiamen

    23 papers led
    No open trial led
  129. 22 papers led
    No open trial led
  130. 21 papers led
    No open trial led
  131. Central Hospital Affiliated to Shandong First Medical University

    山东第一医科大学附属中心医院(济南市中心医院)Jinan

    21 papers led
  132. 21 papers led
    No open trial led
  133. Fourth Hospital of Sichuan University

    四川大学华西第四医院Chengdu

    21 papers led
    No open trial led
  134. Hangzhou First People's Hospital

    杭州市第一人民医院Hangzhou

    21 papers led
    No open trial led
  135. 21 papers led
    No open trial led
  136. 20 papers led
    No open trial led
  137. 20 papers led
    No open trial led
  138. 20 papers led
    No open trial led
  139. 20 papers led
    No open trial led
  140. 20 papers led
    No open trial led
  141. Plastic Surgery Hospital

    中国医学科学院整形外科医院Beijing

    20 papers led
    No open trial led
  142. 20 papers led
    No open trial led
  143. 20 papers led
    No open trial led
  144. 20 papers led
    No open trial led
  145. 19 papers led
    No open trial led
  146. 19 papers led
    No open trial led
  147. 19 papers led
    No open trial led
  148. 19 papers led
    No open trial led
  149. 19 papers led
    No open trial led
  150. Jinling Hospital

    东部战区总医院(金陵医院)Nanjing

    19 papers led
    No open trial led
  151. 19 papers led
    No open trial led
  152. 19 papers led
    No open trial led
  153. 18 papers led
    No open trial led
  154. 18 papers led
    No open trial led
  155. International Cancer Center

    深圳大学卡尔森国际肿瘤中心Shenzhen

    18 papers led
    No open trial led
  156. 18 papers led
    No open trial led
  157. Gynecology Hospital, Fudan University

    复旦大学附属妇产科医院Shanghai

    17 papers led
    No open trial led
  158. 17 papers led
  159. 17 papers led
    No open trial led
  160. 16 papers led
  161. First People's Hospital of Foshan

    佛山市第一人民医院Foshan

    16 papers led
    No open trial led
  162. 16 papers led
  163. Ningbo Medical Center Lihuili Hospital

    宁波市医疗中心李惠利医院Ningbo

    16 papers led
    No open trial led
  164. 16 papers led
  165. 16 papers led
  166. Taizhou Hospital, Wenzhou Medical University

    温州医科大学附属台州医院Taizhou

    15 papers led
    No open trial led
  167. Beijing Tongren Hospital

    首都医科大学附属北京同仁医院Beijing

    14 papers led
    No open trial led
  168. Tangdu Hospital

    空军军医大学唐都医院Xi'an

    14 papers led
  169. Children Hospital

    广东省妇幼保健院Guangzhou

    13 papers led
    No open trial led
  170. Guang'anmen Hospital

    中国中医科学院广安门医院Beijing

    12 papers led
  171. 12 papers led
    No open trial led
  172. Xuanwu Hospital

    首都医科大学宣武医院Beijing

    12 papers led
    No open trial led
  173. 11 papers led
    No open trial led
  174. 11 papers led
  175. Changhai Hospital

    海军军医大学第一附属医院(长海医院)Shanghai

    10 papers led
  176. 10 papers led
    No open trial led
  177. Shanxi Cancer Hospital

    山西省肿瘤医院Taiyuan

    10 papers led
    No open trial led
  178. 9 papers led
    No open trial led
  179. 9 papers led
    No open trial led
  180. 8 papers led
  181. Chongqing General Hospital

    重庆大学附属中心医院(重庆市人民医院)Chongqing

    7 papers led
    No open trial led
  182. 7 papers led
  183. 7 papers led
    No open trial led
  184. Anyang Tumor Hospital

    安阳市肿瘤医院Anyang

    6 papers led
    No open trial led
  185. Shantou Central Hospital

    汕头市中心医院Shantou

    6 papers led
  186. 6 papers led
    No open trial led
  187. 5 papers led
  188. 5 papers led
  189. 4 papers led
    No open trial led
  190. 4 papers led
    No open trial led
  191. Linyi Cancer Hospital

    临沂市肿瘤医院Linyi

    3 papers led
    No open trial led
  192. Wuhan Children's Hospital

    武汉市儿童医院Wuhan

    3 papers led
    No open trial led
  193. Xuzhou Central Hospital

    徐州市中心医院Xuzhou

    3 papers led
    No open trial led
  194. Jilin Cancer Hospital

    吉林省肿瘤医院Changchun

    2 papers led
    No open trial led
  195. PLA Navy Anqing Hospital

    中国人民解放军海军安庆医院Anqing

    2 papers led
    No open trial led
  196. Qingdao Central Hospital

    康复大学青岛中心医院Qingdao

    2 papers led
    No open trial led
  197. 1 paper led
    No open trial led
  198. Handan First Hospital

    邯郸市第一医院Handan

    1 paper led
    No open trial led
  199. 1 paper led
    No open trial led
  200. 1 paper led
    No open trial led
  201. 1 paper led
    No open trial led
  202. Shanghai Proton and Heavy Ion Center

    上海市质子重离子医院Shanghai

    1 paper led
  203. Taizhou Hospital

    浙江省台州医院Taizhou

    1 paper led
  204. Yishui Central Hospital

    临沂市中心医院Linyi

    1 paper led
    No open trial led
  205. 0 papers led
    No open trial led
  206. 0 papers led
  207. 0 papers led
  208. 0 papers led
    No open trial led
  209. 0 papers led
  210. 0 papers led
  211. 0 papers led
    No open trial led
  212. 0 papers led
  213. 0 papers led
    No open trial led
  214. Fuda Cancer Hospital

    广州复大肿瘤医院Guangzhou

    0 papers led
    No open trial led
  215. 0 papers led
  216. Jiangsu Provincial People's Hospital

    江苏省人民医院(南京医科大学第一附属医院)Nanjing

    0 papers led
    No open trial led
  217. Third Affiliated Hospital of Harbin Medical University

    哈尔滨医科大学第三临床医学院Harbin

    0 papers led
    No open trial led
  218. Xuzhou Second People's Hospital

    徐州市第二人民医院Xuzhou

    0 papers led
    No open trial led
  219. 0 papers led

By university or health system 60

Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.

  1. Peking Union Medical College / Chinese Academy of Medical Sciences

    北京协和医学院/中国医学科学院Beijing

    589 papers led
    6 hospitals
  2. Fudan University

    复旦大学Shanghai

    585 papers led
    6 hospitals
  3. Sun Yat-sen University

    中山大学Guangzhou

    529 papers led
    6 hospitals
  4. Nanjing Medical University

    南京医科大学Nanjing

    440 papers led
    6 hospitals
  5. Shanghai Jiao Tong University School of Medicine

    上海交通大学医学院Shanghai

    398 papers led
    6 hospitals
  6. Sichuan University (West China)

    四川大学华西Chengdu

    373 papers led
    6 hospitals
  7. Peking University Health Science Center

    北京大学医学部Beijing

    323 papers led
    6 hospitals
  8. Zhejiang University School of Medicine

    浙江大学医学院Hangzhou

    312 papers led
    6 hospitals
  9. China Medical University (Shenyang)

    中国医科大学Shenyang

    297 papers led
    6 hospitals
  10. Harbin Medical University

    哈尔滨医科大学Harbin

    293 papers led
    6 hospitals
  11. Tianjin Medical University

    天津医科大学Tianjin

    285 papers led
    6 hospitals
  12. Shandong University

    山东大学Jinan

    274 papers led
    6 hospitals
  13. Zhengzhou University

    郑州大学Zhengzhou

    266 papers led
    6 hospitals
  14. Chongqing Medical University

    重庆医科大学Chongqing

    263 papers led
    6 hospitals
  15. Central South University (Xiangya)

    中南大学湘雅Changsha

    260 papers led
    6 hospitals
  16. Huazhong Univ. of Sci. & Tech. – Tongji Medical College

    华中科技大学同济医学院Wuhan

    258 papers led
    6 hospitals
  17. Fujian Medical University

    福建医科大学Fuzhou

    252 papers led
    6 hospitals
  18. Xi'an Jiaotong University

    西安交通大学Xi'an

    240 papers led
    6 hospitals
  19. Capital Medical University

    首都医科大学Beijing

    207 papers led
    6 hospitals
  20. Jilin University

    吉林大学Changchun

    190 papers led
    3 hospitals
  21. Wenzhou Medical University

    温州医科大学Wenzhou

    188 papers led
    6 hospitals
  22. Southern Medical University

    南方医科大学Guangzhou

    186 papers led
    6 hospitals
  23. Qingdao University

    青岛大学Qingdao

    181 papers led
    6 hospitals
  24. Shandong First Medical University

    山东第一医科大学Jinan

    178 papers led
    6 hospitals
  25. Wuhan University

    武汉大学Wuhan

    168 papers led
    2 hospitals
  26. Hebei Medical University

    河北医科大学Shijiazhuang

    160 papers led
    5 hospitals
  27. Tongji University

    同济大学Shanghai

    144 papers led
    6 hospitals
  28. Soochow University

    苏州大学Suzhou

    143 papers led
    6 hospitals
  29. Anhui Medical University

    安徽医科大学Hefei

    136 papers led
    6 hospitals
  30. Chongqing University

    重庆大学Chongqing

    131 papers led
    6 hospitals
  31. Guangxi Medical University

    广西医科大学Nanning

    122 papers led
    6 hospitals
  32. Guangzhou Medical University

    广州医科大学Guangzhou

    119 papers led
    6 hospitals
  33. 118 papers led
    6 hospitals
  34. Southwest Medical University

    西南医科大学Luzhou

    116 papers led
    1 hospital
  35. Xiamen University

    厦门大学Xiamen

    114 papers led
    6 hospitals
  36. University of Chinese Academy of Sciences

    中国科学院大学Beijing

    110 papers led
    1 hospital
  37. Jinan University

    暨南大学Guangzhou

    107 papers led
    6 hospitals
  38. 100 papers led
    3 hospitals
  39. 97 papers led
    3 hospitals
  40. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    91 papers led
    1 hospital
  41. Kunming Medical University

    昆明医科大学Kunming

    90 papers led
    6 hospitals
  42. Nanchang University

    南昌大学Nanchang

    89 papers led
    6 hospitals
  43. Army Medical University

    陆军军医大学Chongqing

    88 papers led
    3 hospitals
  44. Shantou University Medical College

    汕头大学医学院Shantou

    88 papers led
    1 hospital
  45. Nanjing University

    南京大学Nanjing

    87 papers led
    4 hospitals
  46. Air Force Medical University

    空军军医大学Xi'an

    85 papers led
    6 hospitals
  47. Shenzhen University

    深圳大学Shenzhen

    83 papers led
    6 hospitals
  48. Bengbu Medical University

    蚌埠医科大学Bengbu

    79 papers led
    1 hospital
  49. Nantong University

    南通大学Nantong

    78 papers led
    2 hospitals
  50. Xuzhou Medical University

    徐州医科大学Xuzhou

    78 papers led
    6 hospitals
  51. Xinjiang Medical University

    新疆医科大学Urumqi

    66 papers led
    6 hospitals
  52. Guangdong Medical University

    广东医科大学Zhanjiang

    60 papers led
    6 hospitals
  53. Jiangnan University

    江南大学Wuxi

    58 papers led
    6 hospitals
  54. Guizhou Medical University

    贵州医科大学Guiyang

    55 papers led
    3 hospitals
  55. Ningxia Medical University

    宁夏医科大学Yinchuan

    53 papers led
    4 hospitals
  56. Naval Medical University

    海军军医大学Shanghai

    28 papers led
    5 hospitals
  57. Guilin Medical University

    桂林医学院Guilin

    26 papers led
    1 hospital
  58. Chengdu University

    成都大学Chengdu

    24 papers led
    1 hospital
  59. Guangdong Pharmaceutical University

    广东药科大学Guangzhou

    24 papers led
    1 hospital
  60. Jishou University

    吉首大学Jishou

    2 papers led
    1 hospital

754

open trials on breast cancer in China

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with at least one listed hospital as lead sponsor or site. 597 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.

Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial

What the phases mean (US National Cancer Institute)

  1. Recruiting
    Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT06462092

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Huizhou Hospital of Guangzhou Medical UniversityHuizhou

  2. Recruiting
    A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT06889610

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  3. Recruiting
    Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
    Phase
    Not given
    Started
    2026-05
    Posted
    Registry
    NCT06993506

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMS; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Hefei, Shanghai, Shijiazhuang, Wuhan, Xiamen, Yantai, Zhengzhou

  4. Recruiting
    The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
    Phase
    Not given
    Started
    2026-09
    Posted
    Registry
    NCT07039474

    Age 18 years to 75 years (registered criteria)

    Led by Peking University First HospitalBeijing

  5. Recruiting
    Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07084519

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  6. Recruiting
    The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07203729

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  7. Recruiting
    A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07208149

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Changsha, Wuhan

  8. Recruiting
    Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07235176

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  9. Recruiting
    A Cohort Study of Combined Cryoablation and Thermal Ablation for Non-surgical Treatment of Breast Cancer Patients
    Phase
    N/A
    Started
    2026-03
    Posted
    Registry
    NCT07238894

    Age 18 years to 80 years; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  10. Recruiting
    A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07281976

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Guangzhou, Harbin, Nanjing, Shenyang, Zhengzhou

  11. Recruiting
    Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07283692

    Age 18 years to 70 years; women only (registered criteria)

    Led by Renji HospitalShanghai

  12. Recruiting
    A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2026-02
    Posted
    Registry
    NCT07294508

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  13. Recruiting
    A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07321015

    Age 18 years to 75 years; women only (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  14. Recruiting
    QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07342283

    Age 18 years to Not stated (registered criteria)

    Led by Affiliated Hospital of Nantong UniversityNantong

  15. Recruiting
    A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07347600

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Weifang, Wuhan, Xi'an, Xiamen, Yangzhou, Zhengzhou

  16. Recruiting
    A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07349069

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

  17. Recruiting
    A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Cancer
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07352930

    Age 18 years to Not stated; women only (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  18. Recruiting
    A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07354022

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  19. Recruiting
    Study on the Cosmetic Outcome and Safety Evaluation of 3D Printed Biodegradable Biological Mesh for One-Stage Breast Reconstruction After Radical Mastectomy
    Phase
    N/A
    Started
    2026-01
    Posted
    Registry
    NCT07365267

    Age 18 years to 70 years; women only (registered criteria)

    Led by Xijing HospitalXi'an

  20. Recruiting
    CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07366112

    Age 18 years to 75 years; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  21. Recruiting
    Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07372079

    Age 18 years to 75 years; women only (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  22. Recruiting
    The Prognostic Impact of HER2 Expression in Non-Metastatic HER2-Positive Breast Cancer Treated With Dual HER2-Targeted Therapy
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07376174

    Age 18 years to Not stated; women only (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  23. Recruiting
    Response-Based Local Therapy for Regionally Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07376538

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  24. Recruiting
    FMD and Neoadjuvant Chemo-immunotherapy in TNBC
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07378306

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  25. Recruiting
    the Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07380646

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  26. Recruiting
    Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07383818

    Age 18 years to 70 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 4 listed hospitals as study sitesHangzhou, Harbin, Hefei, Shanghai, Xi'an

  27. Recruiting
    A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07389733

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Dalian

  28. Recruiting
    Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07393425

    Age 18 years to 70 years; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  29. Recruiting
    Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07396324

    Age 18 years to Not stated (registered criteria)

    Led by Renji HospitalShanghai

  30. Recruiting
    Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07396454

    Age 18 years to 70 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  31. Recruiting
    Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
    Phase
    Phase 3
    Started
    2026-02
    Posted
    Registry
    NCT07400523

    Age 18 years to Not stated; women only (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 2 listed hospitals as study sitesGuangzhou, Shantou, Zhanjiang

  32. Recruiting
    Efficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy
    Phase
    Phase 2/Phase 3
    Started
    2026-09
    Posted
    Registry
    NCT07410169

    Age 18 years to 75 years; women only (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  33. Recruiting
    RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07413939

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shantou, Tianjin, Urumqi, Wuhan

  34. Recruiting
    CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer(Cinnamon)
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07432178

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  35. Recruiting
    A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07441460

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  36. Recruiting
    Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07457359

    Age 18 years to 75 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  37. Recruiting
    The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors
    Phase
    Early phase 1
    Started
    2026-04
    Posted
    Registry
    NCT07459283

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuxi

  38. Recruiting
    YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07461454

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  39. Recruiting
    Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07471776

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  40. Recruiting
    Ablation Compare With Surgery for Early Breast Cancer
    Phase
    N/A
    Started
    2026-01
    Posted
    Registry
    NCT07484087

    Age 50 years to Not stated; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  41. Recruiting
    Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
    Phase
    Phase 1/Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07486089

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  42. Recruiting
    Electroacupuncture vs. Auricular Acupressure vs. Waitlist Control for Breast Cancer Endocrine Therapy-Related Joint Pain
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07490938

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Teaching Hospital, Tianjin University of Traditional Chinese Medicine; 3 listed hospitals as study sitesTianjin, Wuhan, Xining

  43. Recruiting
    BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07492641

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou

  44. Recruiting
    A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07497386

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  45. Recruiting
    Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07498478

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Linyi, Nanjing, Shanghai, Tianjin, Wuhan

  46. Recruiting
    Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models
    Phase
    Not given
    Started
    2026-03
    Posted
    Registry
    NCT07500428

    Age 18 years to 75 years; women only (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  47. Recruiting
    Large Language Models Assist in Tumor MDT
    Phase
    N/A
    Started
    2026-01
    Posted
    Registry
    NCT07504367

    Age 25 years to 33 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  48. Recruiting
    Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
    Phase
    Phase 1/Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07510802

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  49. Recruiting
    A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07518173

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Guangzhou

  50. Recruiting
    A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07520760

    Age 18 years to Not stated; women only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  51. Recruiting
    Ultra-Hypofractionated vs Moderate Hypofractionated Radiotherapy for Regional Lymph Nodes in High Risk Breast Cancer
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07527689

    Age 18 years to Not stated; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  52. Recruiting
    Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07528716

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  53. Recruiting
    A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07533123

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  54. Recruiting
    A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07540533

    Age 18 years to Not stated (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  55. Recruiting
    Digital Mind-Body Therapy for Neoadjuvant Breast Cancer
    Phase
    N/A
    Started
    2026-03
    Posted
    Registry
    NCT07541664

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  56. Recruiting
    Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07543536

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  57. Recruiting
    A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07544056

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Guangzhou

  58. Recruiting
    Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
    Phase
    Not given
    Started
    2026-05
    Posted
    Registry
    NCT07551050

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  59. Recruiting
    Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
    Phase
    Not given
    Started
    2026-04
    Posted
    Registry
    NCT07552467

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  60. Recruiting
    18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07557225

    Age 18 years to Not stated (registered criteria)

    Led by Peking University First HospitalBeijing

  61. Recruiting
    Opportunistic Breast Cancer Screening Using Non-Contrast Chest CT
    Phase
    Not given
    Started
    2026-05
    Posted
    Registry
    NCT07557654

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  62. Recruiting
    Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07581795

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  63. Recruiting
    Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07581834

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fujian Cancer Hospital; 1 listed hospital as study siteChengdu, Fuzhou

  64. Recruiting
    A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07591090

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  65. Recruiting
    Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer
    Phase
    Phase 4
    Started
    2026-07
    Posted
    Registry
    NCT07600164

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  66. Recruiting
    QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07601178

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Cancer HospitalNanjing

  67. Recruiting
    Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07602907

    Age 18 years to Not stated (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  68. Recruiting
    Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07610720

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  69. Recruiting
    Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07616427

    Age 18 years to 75 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteHangzhou, Nanjing

  70. Recruiting
    Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer
    Phase
    N/A
    Started
    2026-06
    Posted
    Registry
    NCT07616440

    Age 18 years to 70 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  71. Recruiting
    Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07616453

    Age 18 years to 75 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  72. Recruiting
    A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.
    Phase
    N/A
    Started
    2026-06
    Posted
    Registry
    NCT07622836

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  73. Recruiting
    Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07623577

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  74. Recruiting
    Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07638852

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  75. Recruiting
    Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07647016

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  76. Recruiting
    A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07647029

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  77. Recruiting
    Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07647263

    Age 18 years to Not stated; women only (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  78. Recruiting
    A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)
    Phase
    Phase 3
    Started
    2026-07
    Posted
    Registry
    NCT07648914

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  79. Recruiting
    A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07658183

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  80. Recruiting
    Precision Navigation to Improve Community Cancer Screening Participation
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07676383

    Age 45 years to 74 years (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  81. Recruiting
    A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07678957

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  82. Recruiting
    Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer
    Phase
    Phase 4
    Started
    2026-05
    Posted
    Registry
    NCT07695259

    Age 60 years to Not stated; women only (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  83. Recruiting
    Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects
    Phase
    Phase 1/Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07697443

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chengdu, Guangzhou, Meizhou, Tianjin, Wuhan

  84. Recruiting
    Breast Ultrasound Screening in Elderly Women: A Multicenter Cluster Randomized Trial
    Phase
    N/A
    Started
    2026-09
    Posted
    Registry
    NCT07698366

    Age 65 years to 80 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  85. Recruiting
    Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast Cancer
    Phase
    Not given
    Started
    2026-06
    Posted
    Registry
    NCT07702708

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fujian Cancer Hospital; 2 listed hospitals as study sitesFuzhou, Quanzhou

  86. Recruiting
    Exergames-acceptance and Commitment Therapy(e-ACT) for Breast Cancer Depression and Anxiety: A Randomized Controlled Trial
    Phase
    N/A
    Started
    2026-03
    Posted
    Registry
    NCT07721753

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteXinxiang

  87. Recruiting
    SMP-656 for HER2-Positive Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07726342

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shenyang, Shijiazhuang, Wuhan, Xi'an, Zhengzhou

  88. Recruiting
    A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)
    Phase
    Phase 3
    Started
    2026-09
    Posted
    Registry
    NCT07729956

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  89. Recruiting
    Culmerciclib in HR+/HER2+ Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07732491

    Age 18 years to Not stated; women only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  90. Recruiting
    GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)
    Phase
    Phase 1/Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07738341

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  91. Recruiting
    Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study
    Phase
    Phase 1/Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07739485

    Age 18 years to 70 years; women only (registered criteria)

    Led by Affiliated Hospital of Guizhou Medical UniversityGuiyang

  92. Recruiting
    Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study
    Phase
    Phase 1/Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07739511

    Age 18 years to 70 years; women only (registered criteria)

    Led by Affiliated Hospital of Guizhou Medical UniversityGuiyang

  93. Recruiting
    A Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.
    Phase
    Not given
    Started
    2026-08
    Posted
    Registry
    NCT07743944

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  94. Recruiting
    A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2026-08
    Posted
    Registry
    NCT07753226

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  95. Recruiting
    A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07757230

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  96. Recruiting
    68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07760012

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Third HospitalBeijing

  97. Recruiting
    Analysis of Multimodal Psychosomatic Comorbidity Burden in Breast Cancer and Benefit Evaluation of Acupuncture Collaborative Management Regimen
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07763587

    Age 18 years to 70 years; women only (registered criteria)

    Led by First Teaching Hospital, Tianjin University of Traditional Chinese Medicine; 1 listed hospital as study siteTianjin

  98. Recruiting
    Establishment of a Multi-omics Prediction Model for Early Triple-negative Breast Cancer Based on UPGRADE-TNBC Study
    Phase
    Not given
    Started
    2026-08
    Posted
    Registry
    NCT07773818

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  99. Recruiting
    Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07796880

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  100. Recruiting
    Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC
    Phase
    Phase 3
    Started
    2026-07
    Posted
    Registry
    NCT07797218

    Age 18 years to 70 years; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  101. Recruiting
    Risk-Stratified Management of Inavolisib-Induced Hyperglycemia and Patient Adherence
    Phase
    Not given
    Started
    2026-04
    Posted
    Registry
    NCT07817056

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  102. Recruiting
    Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07817082

    Age 18 years to 75 years; women only (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  103. Recruiting
    Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Systemic Therapy
    Phase
    N/A
    Started
    2026-09
    Posted
    Registry
    NCT07829848

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  104. Recruiting
    1-Week Versus 3-Week PBI
    Phase
    N/A
    Started
    2026-10
    Posted
    Registry
    NCT07832279

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  105. Recruiting
    CAIX-targeted PET/CT in Solid Tumors
    Phase
    N/A
    Started
    2026-09
    Posted
    Registry
    NCT07833085

    Age 18 years to Not stated (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

  106. Recruiting
    Hypofractionated vs. Conventionally Fractionated Postmastectomy Radiotherapy After Implant-Based Reconstruction
    Phase
    N/A
    Started
    2026-10
    Posted
    Registry
    NCT07835139

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  107. Recruiting
    Artificial Intelligence (AI)-Based Personalized Exercise Coaching for Patients With Breast Cancer
    Phase
    N/A
    Started
    2026-07
    Posted
    Registry
    NCT07844941

    Age 18 years to 70 years; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  108. Recruiting
    Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07848243

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  109. Recruiting
    A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07876557

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Jinan, Lanzhou, Nanchang, Nanjing, Qingdao, Shenyang, Shijiazhuang, Taiyuan, Weifang, Wuhan, Yinchuan, Zhengzhou

  110. Recruiting
    Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
    Phase
    Not given
    Started
    2026-10
    Posted
    Registry
    NCT07880106

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  111. Recruiting
    Pre-Treatment Breast DCE-MRI AI Model to Predict Neoadjuvant Chemotherapy Benefit in Locally Advanced Triple-Negative Breast Cancer
    Phase
    Not given
    Started
    2026-10
    Posted
    Registry
    NCT07880600

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fujian Cancer Hospital; 2 listed hospitals as study sitesFuzhou, Quanzhou

  112. Recruiting
    A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07900516

    Age 18 years to 75 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  113. Recruiting
    Thalidomide for Preventing Radiation-Induced Dermatitis in Breast Cancer Patients
    Phase
    N/A
    Started
    2026-11
    Posted
    Registry
    NCT07933653

    Age 18 years to 70 years; women only (registered criteria)

    Led by First Affiliated Hospital of Guangxi Medical UniversityNanning

  114. Recruiting
    Nectin-4 Specific LMW PET Probe Imaging in Multiple Solid Tumors
    Phase
    N/A
    Started
    2025-05
    Posted
    Registry
    NCT05321316

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  115. Recruiting
    Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer
    Phase
    Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT06637150

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  116. Recruiting
    ARX788 in HER2-positive Metastatic Breast Cancer Patients
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06663748

    Age 18 years to 75 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  117. Recruiting
    A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients
    Phase
    Phase 1/Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06679036

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Zhengzhou

  118. Recruiting
    A Phase II Clinical Trial of Artificial Intelligence-assisted One-stop Radiotherapy for Breast Cancer After Breast-conserving Surgery
    Phase
    N/A
    Started
    2025-04
    Posted
    Registry
    NCT06686459

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  119. Recruiting
    Reverse HER2-negative Immune Resistant Breast Cancer
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06731140

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  120. Recruiting
    A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
    Phase
    Phase 1
    Started
    2025-03
    Posted
    Registry
    NCT06738966

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangchun, Jinan

  121. Recruiting
    Effects of TDCS Intervention on Neoadjuvant Chemotherapy in Breast Cancer Patients with Mild to Moderate Depression
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT06741540

    Age 18 years to 65 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  122. Recruiting
    BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
    Phase
    Phase 1
    Started
    2025-02
    Posted
    Registry
    NCT06756932

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai, Tianjin, Zhengzhou

  123. Recruiting
    Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06757634

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shenyang, Tianjin, Weifang, Xi'an, Xinxiang, Yangzhou, Zhengzhou

  124. Recruiting
    AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
    Phase
    Phase 3
    Started
    2025-02
    Posted
    Registry
    NCT06767527

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  125. Recruiting
    HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-05
    Posted
    Registry
    NCT06769425

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  126. Recruiting
    Electroacupuncture Treatment of Peripheral Neuropathy After Taxane Chemotherapy for Breast Cancer
    Phase
    N/A
    Started
    2025-06
    Posted
    Registry
    NCT06772935

    Age 18 years to 75 years; women only (registered criteria)

    Led by Affiliated Hospital of Qinghai UniversityXining

  127. Recruiting
    To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT06784921

    Age 18 years to 75 years; women only (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  128. Recruiting
    Capecitabine in Low Risk Triple Negative Breast Cancer
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06787339

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  129. Recruiting
    A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06790693

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Kunming, Nanning, Tianjin, Urumqi, Xi'an, Xiangyang

  130. Recruiting
    BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06793332

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  131. Recruiting
    Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06802757

    Age 18 years to 70 years; women only (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  132. Recruiting
    A Phase IIa Study to Evaluate NBQ72S
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06810804

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  133. Recruiting
    A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Breast Cancer Patients
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06811870

    Age 18 years to 60 years; women only (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  134. Recruiting
    To Evaluate the Effectiveness and Safety of Mastectomy Combined With Immediate Breast Reconstruction in Breast Cancer (NJMU-Reconstruction Cohort)
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT06817954

    Age 18 years to 75 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  135. Recruiting
    A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06827236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBengbu, Changchun, Chengdu, Chongqing, Nanning, Shanghai, Xi'an

  136. Recruiting
    Hypofractionated Radiation Fractionation in Breast Cancer Patients With Implant-Based Reconstruction
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT06830083

    Age 18 years to 65 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  137. Recruiting
    A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06830889

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

  138. Recruiting
    A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06832202

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  139. Recruiting
    A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug as a Radiosensitizer in Patients With Advanced Breast Cancer Brain Metastasis.
    Phase
    Not given
    Started
    2025-03
    Posted
    Registry
    NCT06839547

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  140. Recruiting
    Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06839560

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  141. Recruiting
    A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06841354

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanjing, Nanning, Taiyuan, Taizhou, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  142. Recruiting
    JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-02
    Posted
    Registry
    NCT06846437

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  143. Recruiting
    Phase I-II Clinical Study of Taurine for External Use in the Prevention and Treatment of Acute Radiation Skin Injury
    Phase
    Phase 1/Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06847555

    Age 18 years to Not stated; women only (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  144. Recruiting
    The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06851299

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  145. Recruiting
    A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
    Phase
    N/A
    Started
    2025-02
    Posted
    Registry
    NCT06856200

    Age 18 years to Not stated (registered criteria)

    Led by Cancer Hospital, Fudan UniversityShanghai

  146. Recruiting
    Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06860529

    Age 18 years to Not stated (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  147. Recruiting
    Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)
    Phase
    Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06874933

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesHangzhou

  148. Recruiting
    Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
    Phase
    Phase 3
    Started
    2025-02
    Posted
    Registry
    NCT06889688

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 4 listed hospitals as study sitesChangsha, Guangzhou, Guiyang, Shanghai, Wuhan

  149. Recruiting
    A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06891833

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesAnyang, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Luoyang, Nanchang, Nanning, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  150. Recruiting
    Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients
    Phase
    N/A
    Started
    2025-08
    Posted
    Registry
    NCT06892093

    Age 18 years to Not stated; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  151. Recruiting
    Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
    Phase
    Phase 1
    Started
    2025-01
    Posted
    Registry
    NCT06900647

    Age 18 years to Not stated; women only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  152. Recruiting
    Study on the Use of Lateral Decubitus Position in Left Breast Cancer Patients Undergoing Adjuvant Radiotherapy
    Phase
    N/A
    Started
    2025-04
    Posted
    Registry
    NCT06902051

    Age 18 years to 70 years; women only (registered criteria)

    Led by Nanfang HospitalGuangzhou

  153. Recruiting
    Topical Diclofenac for Prevention of Radiation-induced Dermatitis
    Phase
    N/A
    Started
    2025-02
    Posted
    Registry
    NCT06905561

    Age 18 years to 75 years (registered criteria)

    Led by Hainan General Hospital / Hainan Medical University hospitalsHaikou

  154. Recruiting
    Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06908668

    Age 18 years to 70 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  155. Recruiting
    Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT06909604

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  156. Recruiting
    Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06914440

    Age 18 years to 75 years; women only (registered criteria)

    Led by Xijing HospitalXi'an

  157. Recruiting
    Clinical Study of 18F-Labeled FAPI-04 in PET Imaging of Breast Cancer
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT06916338

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Qingdao UniversityQingdao

  158. Recruiting
    Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT06916637

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Qingdao UniversityQingdao

  159. Recruiting
    A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
    Phase
    Phase 2/Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT06926868

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesAnyang, Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanning, Qingdao, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou

  160. Recruiting
    SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06927180

    Age 18 years to 70 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  161. Recruiting
    Clinical Efficacy and Safety Assessment of Breast-Conserving Surgery for Central Breast Cancer: A Prospective Randomized Controlled Trial
    Phase
    N/A
    Started
    2025-02
    Posted
    Registry
    NCT06938360

    Age 18 years to 70 years; women only (registered criteria)

    Led by Xijing HospitalXi'an

  162. Recruiting
    Development and Application of Accurate Detection Technology Based on Multimodal Data of Breast Cancer Comobid Depression
    Phase
    Not given
    Started
    2025-03
    Posted
    Registry
    NCT06938373

    Age 18 years to 80 years (registered criteria)

    Led by Xiangya HospitalChangsha

  163. Recruiting
    Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06942234

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  164. Recruiting
    Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT06952920

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Qinghai UniversityXining

  165. Recruiting
    A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2025-05
    Posted
    Registry
    NCT06957886

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Guangzhou

  166. Recruiting
    Neoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive /HER2-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06964906

    Age 18 years to 75 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  167. Recruiting
    A Real World Study of Sacituzumab Govitecan
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT06966141

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  168. Recruiting
    A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06966700

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Hangzhou, Harbin, Hefei, Jinan, Nanjing, Nanning, Shanghai, Urumqi, Wuhan, Xi'an, Xiamen, Zhengzhou

  169. Recruiting
    QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT06967103

    Age 18 years to Not stated (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  170. Recruiting
    ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT06970912

    Age 18 years to 75 years; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  171. Recruiting
    A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06974929

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  172. Recruiting
    Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06977893

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 9 listed hospitals as study sitesHangzhou, Harbin, Hefei, Nanchang, Shanghai, Urumqi, Xi'an, Zhengzhou

  173. Recruiting
    Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration
    Phase
    Not given
    Started
    2025-05
    Posted
    Registry
    NCT06991790

    Age 18 years to 75 years; women only (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  174. Recruiting
    Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06992336

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  175. Recruiting
    A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06992882

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  176. Recruiting
    3D-printed Biodegradable Breast Implants for Breast Restoration
    Phase
    Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06993714

    Age 18 years to 70 years; women only (registered criteria)

    Led by Xijing HospitalXi'an

  177. Recruiting
    Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06993844

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesFuzhou, Guangzhou, Jinan, Shanghai

  178. Recruiting
    GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT06994507

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  179. Recruiting
    The Application of "HUAXI Hole 1" in Reverse-sequence Endoscopic Nipple-sparing Mastectomy With Direct-to-implant Breast Reconstruction
    Phase
    N/A
    Started
    2025-06
    Posted
    Registry
    NCT06995118

    Age 18 years to 70 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Guangzhou, Nanchang, Zhengzhou

  180. Recruiting
    A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07002177

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  181. Recruiting
    A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT07003074

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChangchun, Changsha, Hefei, Jinan, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Tianjin, Urumqi, Wuhan

  182. Recruiting
    Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07008976

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Fuzhou, Haikou, Hefei, Lanzhou, Linyi, Nanchang, Nanchong, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Zhengzhou

  183. Recruiting
    A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT07010939

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shenzhen, Taiyuan

  184. Recruiting
    A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07024173

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Guangzhou

  185. Recruiting
    Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07037199

    Age 18 years to Not stated; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  186. Recruiting
    Efficacy and Safety of Prepectoral Prosthesis Immediate One-Stage Breast Reconstruction Versus Two-Stage Expander/Prosthesis Reconstruction in Postoperative Adjuvant Radiotherapy Breast Cancer Patients: A Prospective, Single-Center, Cohort Study
    Phase
    Not given
    Started
    2025-05
    Posted
    Registry
    NCT07037576

    Age 18 years to 70 years; women only (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  187. Recruiting
    A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07043725

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 52 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Harbin, Hefei, Hengyang, Jinan, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Xinxiang, Yantai, Zhengzhou

  188. Recruiting
    JS207 Combination Therapy in Triple-negative Breast Cancer
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07045311

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Dalian, Hangzhou, Harbin, Hefei, Nanjing, Qingdao, Shenyang, Shijiazhuang, Urumqi, Wuhan, Xi'an, Zhengzhou

  189. Recruiting
    Trop-2 Targeted PET Probes in Advanced TNBC
    Phase
    N/A
    Started
    2025-03
    Posted
    Registry
    NCT07046455

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  190. Recruiting
    TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07047365

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 44 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guiyang, Haikou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Luzhou, Nanchang, Nanchong, Nanjing, Nanning, Ningbo, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Tangshan, Tianjin, Weifang, Wenzhou, Xi'an, Xiangyang, Xining, Xinxiang, Xuzhou, Zhengzhou

  191. Recruiting
    Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT07057427

    Age 18 years to 70 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  192. Recruiting
    A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07060807

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Taizhou, Urumqi, Xi'an, Xiamen, Xiangyang, Zhengzhou

  193. Recruiting
    A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07062965

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Wenzhou, Wuhan, Xi'an

  194. Recruiting
    Modulating the Skin Microbiome to Prevent Radiation Dermatitis in Breast Cancer
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT07066280

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  195. Recruiting
    A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07071337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Guangzhou

  196. Recruiting
    SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07080619

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  197. Recruiting
    Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07088263

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  198. Recruiting
    Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
    Phase
    N/A
    Started
    2025-08
    Posted
    Registry
    NCT07095023

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Guiyang, Shantou, Shenzhen, Wenzhou

  199. Recruiting
    Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients
    Phase
    Phase 1
    Started
    2025-06
    Posted
    Registry
    NCT07096869

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun

  200. Recruiting
    A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07100106

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Jinan, Nanning, Shanghai, Tianjin

  201. Recruiting
    Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07100600

    Age 18 years to Not stated; women only (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  202. Recruiting
    A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07111832

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai

  203. Recruiting
    Prospective Study on Exemption of Tumor Bed Boost Radiotherapy for pCR Patients After Breast Conserving Surgery With Neoadjuvant Therapy
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT07113613

    Age 30 years to 75 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  204. Recruiting
    A Study of LY4257496 in Participants With Cancer (OMNIRAY)
    Phase
    Phase 1
    Started
    2025-08
    Posted
    Registry
    NCT07114601

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Tianjin

  205. Recruiting
    An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07117630

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  206. Recruiting
    Exploration of the Safety and Efficacy of T-DXd Concurrent With Brain Radiotherapy in Patients With Brain Metastases HER2-positive/HER2-low Advanced Breast Cancer
    Phase
    N/A
    Started
    2025-07
    Posted
    Registry
    NCT07117864

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  207. Recruiting
    SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07125950

    Age 18 years to Not stated (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  208. Recruiting
    A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07130383

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  209. Recruiting
    Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases
    Phase
    Phase 1/Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT07134153

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  210. Recruiting
    T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07150208

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  211. Recruiting
    T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07152782

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  212. Recruiting
    Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Cancer
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT07154563

    Age 18 years to 75 years; women only (registered criteria)

    Led by Yunnan Cancer HospitalKunming

  213. Recruiting
    Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2025-08
    Posted
    Registry
    NCT07156253

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  214. Recruiting
    Dragon Boat Race Versus Family Unsupervised Training to Improve the Physical Function and Quality of Life in Breast Cancer Patients
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT07162298

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  215. Recruiting
    A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07169994

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesAnyang, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Luoyang, Meizhou, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Xiangyang

  216. Recruiting
    ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
    Phase
    Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT07173751

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesHefei, Jinan, Lanzhou, Linyi, Nanchang, Taiyuan, Wuhan, Xi'an, Zhengzhou

  217. Recruiting
    A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07174336

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Harbin, Shanghai, Shantou, Tianjin, Wuhan

  218. Recruiting
    A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC
    Phase
    Phase 1
    Started
    2025-11
    Posted
    Registry
    NCT07178171

    Age 18 years to 70 years; women only (registered criteria)

    Led by Xijing HospitalXi'an

  219. Recruiting
    Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
    Phase
    Not given
    Started
    2025-08
    Posted
    Registry
    NCT07180056

    Age 18 years to Not stated (registered criteria)

    Led by Renji HospitalShanghai

  220. Recruiting
    Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07180082

    Age 18 years to Not stated (registered criteria)

    Led by Renji HospitalShanghai

  221. Recruiting
    Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07180160

    Age 18 years to Not stated; women only (registered criteria)

    Led by Renji HospitalShanghai

  222. Recruiting
    Trastuzumab Deruxtecan in Advanced Breast Cancer
    Phase
    Not given
    Started
    2025-08
    Posted
    Registry
    NCT07180264

    Age 18 years to Not stated (registered criteria)

    Led by Renji HospitalShanghai

  223. Recruiting
    SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07182721

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  224. Recruiting
    A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
    Phase
    Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07207070

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  225. Recruiting
    A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
    Phase
    Phase 1
    Started
    2025-10
    Posted
    Registry
    NCT07213791

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  226. Recruiting
    An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-12
    Posted
    Registry
    NCT07222267

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Xiamen

  227. Recruiting
    A Study on Predicting the Risk of Distant Metastasis in Breast Cancer Using AI-Generated Spatial Pathological Maps
    Phase
    Not given
    Started
    2025-11
    Posted
    Registry
    NCT07244094

    Age 18 years to 95 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteChangchun, Hangzhou

  228. Recruiting
    A Study on Combined Low-pass Whole-genome and Methylome Testing of Bloody Nipple Discharge Specimens for Benign-Malignant Differentiation.
    Phase
    Not given
    Started
    2025-12
    Posted
    Registry
    NCT07250204

    Age 18 years to Not stated (registered criteria)

    Led by Hubei Cancer HospitalWuhan

  229. Recruiting
    A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-10
    Posted
    Registry
    NCT07250386

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  230. Recruiting
    Clinical Translation Research on a Multi-omics Breast Cancer Distant Metastasis Prediction Model Empowered by Artificial Intelligence
    Phase
    Not given
    Started
    2025-12
    Posted
    Registry
    NCT07252986

    Age not stated; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  231. Recruiting
    Sac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07258108

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  232. Recruiting
    VSV-02 Compassionate Use in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-09
    Posted
    Registry
    NCT07260591

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Xinxiang Medical UniversityXinxiang

  233. Recruiting
    DIEP Flap Breast Reconstruction: Perioperative Biomarkers and Outcomes
    Phase
    Not given
    Started
    2025-12
    Posted
    Registry
    NCT07263347

    Age 18 years to 70 years; women only (registered criteria)

    Led by Hubei Cancer HospitalWuhan

  234. Recruiting
    Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07263425

    Age 18 years to 75 years; women only (registered criteria)

    Led by Jiangsu Province Hospital; 1 listed hospital as study siteNanjing

  235. Recruiting
    Safety and Feasibility of IRE for Early-stage Breast Cancer: a Prospective, Open-Label, Single-Arm, Exploratory Study
    Phase
    N/A
    Started
    2025-12
    Posted
    Registry
    NCT07263451

    Age 18 years to Not stated; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  236. Recruiting
    Gut Microbiota and Diarrhea in Breast Cancer Patients Receiving Pyrotinib
    Phase
    Not given
    Started
    2025-12
    Posted
    Registry
    NCT07264985

    Age 18 years to 75 years (registered criteria)

    Led by Hubei Cancer HospitalWuhan

  237. Recruiting
    Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea
    Phase
    Not given
    Started
    2025-12
    Posted
    Registry
    NCT07264998

    Age 18 years to 75 years (registered criteria)

    Led by Hubei Cancer HospitalWuhan

  238. Recruiting
    A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
    Phase
    Phase 1
    Started
    2025-12
    Posted
    Registry
    NCT07274852

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu

  239. Recruiting
    Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT07284836

    Age 18 years to 70 years; women only (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  240. Recruiting
    Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07285382

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesDalian, Qingdao

  241. Recruiting
    A Prospective Multicenter Study of the TuFEst-LN Model for Axillary Lymph Node Status Assessment in Breast Cancer
    Phase
    Not given
    Started
    2025-08
    Posted
    Registry
    NCT07304934

    Age 18 years to Not stated; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  242. Recruiting
    A Retrospective Analysis of Robot-Assisted Versus Endoscopic Breast-Conserving Surgery for Breast Cancer
    Phase
    N/A
    Started
    2025-06
    Posted
    Registry
    NCT07321145

    Age 18 years to 80 years; women only (registered criteria)

    Led by Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  243. Recruiting
    A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07330544

    Age 18 years to Not stated; women only (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  244. Recruiting
    68Ga-PFA2 PET Imaging for the Diagnosis of Annexin A2-Positive Tumors
    Phase
    Not given
    Started
    2025-06
    Posted
    Registry
    NCT07331532

    Age 18 years to 80 years (registered criteria)

    Led by Peking University First HospitalBeijing

  245. Recruiting
    Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07340398

    Age 18 years to 75 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  246. Recruiting
    A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.
    Phase
    Early phase 1
    Started
    2025-05
    Posted
    Registry
    NCT07340424

    Age 18 years to Not stated; women only (registered criteria)

    Led by Cancer Hospital, Shandong First Medical UniversityJinan

  247. Recruiting
    Observation of the Effect of Preoperative Use of Dexmedetomidine Hydrochloride Nasal Spray on Optimizing Awake Sedation During Breast-Conserving Surgery for Breast Cancer and Postoperative Awake Status
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT07350928

    Age 20 years to 70 years; women only (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  248. Recruiting
    Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07351487

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesHangzhou, Hefei, Shanghai

  249. Recruiting
    Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer
    Phase
    Not given
    Started
    2025-06
    Posted
    Registry
    NCT07358182

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  250. Recruiting
    Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT07362914

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  251. Recruiting
    Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07371208

    Age 18 years to 65 years (registered criteria)

    Led by Ruijin HospitalShanghai

  252. Recruiting
    Acupuncture and Compression for the Prevention of CIPN in Breast Cancer Patients
    Phase
    N/A
    Started
    2025-09
    Posted
    Registry
    NCT07377279

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  253. Recruiting
    ctDNA-guided Treatment Decision-making
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07394218

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  254. Recruiting
    Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT07394387

    Age 18 years to 70 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  255. Recruiting
    Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07401537

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  256. Recruiting
    Real-world Studies of CDK4/6 Inhibitors
    Phase
    Not given
    Started
    2025-06
    Posted
    Registry
    NCT07407439

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  257. Recruiting
    AI-Enhanced Imaging in Population Breast Cancer Screening
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT07411443

    Age 35 years to 69 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  258. Recruiting
    A Study on the Efficacy and Safety of Switching Between Two Targeted Strategies, HP+Chemotherapy and HPy+Chemotherapy, After Treatment Progression in HER-2 Positive Advanced or Metastatic Breast Cancer
    Phase
    Not given
    Started
    2025-03
    Posted
    Registry
    NCT07455188

    Age 18 years to Not stated; women only (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  259. Recruiting
    Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment
    Phase
    Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07467330

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  260. Recruiting
    Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases
    Phase
    N/A
    Started
    2025-10
    Posted
    Registry
    NCT07469267

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 12 listed hospitals as study sitesChangsha, Guiyang, Hangzhou, Harbin, Jinan, Ningbo, Shanghai, Shijiazhuang, Tianjin, Wuhan

  261. Recruiting
    Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07492394

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  262. Recruiting
    Robustness Evaluation of Deep Inspiration Breath-Hold (DIBH) Plans in Internal Mammary Irradiation
    Phase
    Not given
    Started
    2025-10
    Posted
    Registry
    NCT07498855

    Age 18 years to Not stated; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  263. Recruiting
    A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer
    Phase
    Not given
    Started
    2025-09
    Posted
    Registry
    NCT07532434

    Age 18 years to Not stated; women only (registered criteria)

    Led by Peking University Third HospitalBeijing

  264. Recruiting
    Endoscopic Skin-Sparing vs. Conventional Mastectomy for Wound Complications in BC
    Phase
    N/A
    Started
    2025-12
    Posted
    Registry
    NCT07548762

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  265. Recruiting
    Molecular Subtyping of Breast Cancer-derived Small Extracellular Vesicles (sEVs) to Predict Therapeutic Efficacy
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT07574749

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  266. Recruiting
    A Randomized, Self-controlled Post-marketing Clinical Study on the Comparison of Shengbai Oral Liquid and Leucogen Tablets in the Treatment of Moderate Neutropenia Caused by Anti-tumor Drugs in Breast Cancer Patients
    Phase
    Phase 4
    Started
    2025-08
    Posted
    Registry
    NCT07578064

    Age 18 years to 80 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  267. Recruiting
    Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07586826

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  268. Recruiting
    The Value of Time-Dependent Diffusion MRI and Magnetic Resonance Elastography in the Precise Diagnosis and Efficacy Assessment of Breast Cancer
    Phase
    N/A
    Started
    2025-10
    Posted
    Registry
    NCT07608081

    Age 18 years to 80 years; women only (registered criteria)

    Led by Yunnan Cancer HospitalKunming

  269. Recruiting
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07612891

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  270. Recruiting
    A Phase II Observational Clinical Study on the Relationship Between Cerebrospinal Fluid Drug Concentration and Efficacy of Trastuzumab Deruxtecan in Central Nervous System Metastatic Breast Cancer
    Phase
    Not given
    Started
    2025-06
    Posted
    Registry
    NCT07653893

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  271. Recruiting
    Optimal Application Timing of ADC Drugs for Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07657130

    Age 18 years to 75 years; women only (registered criteria)

    Led by Liaoning Cancer Hospital & InstituteShenyang

  272. Recruiting
    A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT07673029

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 51 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Meizhou, Nanchang, Nanning, Qingdao, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xi'an, Xinxiang, Xuzhou, Yantai, Zhengzhou

  273. Recruiting
    Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07708194

    Age 18 years to 75 years; women only (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  274. Recruiting
    Efficacy of Kinesio Taping Versus Compression Therapy on Breast Lymphedema Induced by Radiotherapy After Breast-Conserving Surgery
    Phase
    N/A
    Started
    2025-10
    Posted
    Registry
    NCT07767305

    Age 18 years to Not stated (registered criteria)

    Led by Tangshan People's HospitalTangshan

  275. Recruiting
    Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07810088

    Age 18 years to 75 years; women only (registered criteria)

    Led by Union HospitalWuhan

  276. Recruiting
    Pucotenlimab and Anlotinib in Combination With Chemotherapy
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07896668

    Age 18 years to Not stated (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  277. Recruiting
    Targeted Resection of Axillary Metastatic Lymph Nodes After Breast Cancer Neoadjuvant Chemotherapy
    Phase
    N/A
    Started
    2024-11
    Posted
    Registry
    NCT04744506

    Age 18 years to 85 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  278. Recruiting
    Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer
    Phase
    Not given
    Started
    2024-09
    Posted
    Registry
    NCT05578053

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  279. Recruiting
    Organoid-based Functional Precision Therapy for Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06102824

    Age 18 years to 80 years (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  280. Recruiting
    Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2024-01
    Posted
    Registry
    NCT06149130

    Age 18 years to 75 years; women only (registered criteria)

    Led by Tongji HospitalWuhan

  281. Recruiting
    A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
    Phase
    Phase 2
    Started
    2024-02
    Posted
    Registry
    NCT06172478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Guangzhou

  282. Recruiting
    Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial
    Phase
    Phase 2
    Started
    2024-01
    Posted
    Registry
    NCT06176534

    Age 18 years to Not stated (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  283. Recruiting
    Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
    Phase
    N/A
    Started
    2024-01
    Posted
    Registry
    NCT06197581

    Age 18 years to 70 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  284. Recruiting
    Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer
    Phase
    Phase 3
    Started
    2024-01
    Posted
    Registry
    NCT06200168

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Qinghai UniversityXining

  285. Recruiting
    A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT06210776

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Kunming, Luoyang, Nanchang, Nanjing, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Taiyuan, Tangshan, Tianjin, Urumqi, Weifang, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou, Zhuhai

  286. Recruiting
    The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
    Phase
    Phase 3
    Started
    2024-01
    Posted
    Registry
    NCT06214195

    Age 18 years to Not stated (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  287. Recruiting
    Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis
    Phase
    Phase 4
    Started
    2024-01
    Posted
    Registry
    NCT06230055

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  288. Recruiting
    A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC
    Phase
    N/A
    Started
    2024-02
    Posted
    Registry
    NCT06235931

    Age 65 years to Not stated; women only (registered criteria)

    Led by Second Affiliated Hospital of Soochow UniversitySuzhou

  289. Recruiting
    The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study
    Phase
    Phase 2
    Started
    2024-01
    Posted
    Registry
    NCT06254690

    Age 18 years to 70 years; women only (registered criteria)

    Led by Jiangsu Province Hospital; 1 listed hospital as study siteNanjing

  290. Recruiting
    Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2024-06
    Posted
    Registry
    NCT06255392

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  291. Recruiting
    Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer
    Phase
    Phase 2
    Started
    2024-01
    Posted
    Registry
    NCT06276868

    Age 18 years to 70 years; women only (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  292. Recruiting
    Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT06282796

    Age 18 years to 80 years; women only (registered criteria)

    Led by First Hospital of China Medical University; 2 listed hospitals as study sitesFuzhou, Shenyang

  293. Recruiting
    Dalpiciclib in HR+/HER2- ABC
    Phase
    Not given
    Started
    2024-05
    Posted
    Registry
    NCT06301438

    Age 18 years to Not stated (registered criteria)

    Led by Renji HospitalShanghai

  294. Recruiting
    DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2024-03
    Posted
    Registry
    NCT06313086

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  295. Recruiting
    Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy
    Phase
    Phase 3
    Started
    2024-03
    Posted
    Registry
    NCT06313463

    Age 18 years to 80 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  296. Recruiting
    Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
    Phase
    Phase 3
    Started
    2024-03
    Posted
    Registry
    NCT06314906

    Age 18 years to 75 years (registered criteria)

    Led by Lanzhou University Second HospitalLanzhou

  297. Recruiting
    Minimal Access Versus Conventional Latissimus Dorsi Flap Harvest for Breast Reconstruction
    Phase
    N/A
    Started
    2024-03
    Posted
    Registry
    NCT06319157

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  298. Recruiting
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
    Phase
    Phase 1/Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06324357

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou

  299. Recruiting
    SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06340230

    Age 18 years to 75 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  300. Recruiting
    Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer
    Phase
    Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06367088

    Age 18 years to 70 years (registered criteria)

    Led by Union HospitalWuhan

  301. Recruiting
    A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.
    Phase
    N/A
    Started
    2024-10
    Posted
    Registry
    NCT06371274

    Age 18 years to Not stated; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  302. Recruiting
    A Study of GC203 TIL in Advanced Malignant Solid Tumors
    Phase
    Phase 1
    Started
    2024-05
    Posted
    Registry
    NCT06375187

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  303. Recruiting
    A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
    Phase
    Phase 3
    Started
    2024-07
    Posted
    Registry
    NCT06383767

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  304. Recruiting
    Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy
    Phase
    Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06385990

    Age 18 years to 70 years; women only (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  305. Recruiting
    LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06387628

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  306. Recruiting
    clinIcal Efficacy and Safety of Incadronate in Breast Cancer With Bone Metastases
    Phase
    Not given
    Started
    2024-03
    Posted
    Registry
    NCT06392217

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  307. Recruiting
    SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06401005

    Age 18 years to Not stated; women only (registered criteria)

    Led by Hubei Cancer HospitalWuhan

  308. Recruiting
    SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06402435

    Age 18 years to Not stated; women only (registered criteria)

    Led by Hubei Cancer HospitalWuhan

  309. Recruiting
    Boost Irradiation to the Supraclavicular Area Among High Risk cN3c Breast Cancer Patients
    Phase
    Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06404697

    Age 18 years to Not stated; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  310. Recruiting
    Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer
    Phase
    Early phase 1
    Started
    2024-05
    Posted
    Registry
    NCT06411678

    Age 18 years to 70 years; women only (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  311. Recruiting
    Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06418594

    Age 18 years to Not stated; women only (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  312. Recruiting
    The Impact of Socioeconomic Determinants on the Patient Reported Outcomes in Young Breast Cancer Patients After Breast Surgery
    Phase
    Not given
    Started
    2024-02
    Posted
    Registry
    NCT06425874

    Age 18 years to 50 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  313. Recruiting
    Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06433609

    Age 18 years to 75 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  314. Recruiting
    A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06439771

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  315. Recruiting
    The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06452706

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesHangzhou, Harbin, Shanghai, Urumqi, Wuhan, Xi'an

  316. Recruiting
    Randomized Phase II Trial: Chest Wall RT Omission After Prosthetic Reconstruction
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06464913

    Age 18 years to 70 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  317. Recruiting
    A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Posted
    Registry
    NCT06465069

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

  318. Recruiting
    A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06471205

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  319. Recruiting
    A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06492005

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  320. Recruiting
    A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-08
    Posted
    Registry
    NCT06493864

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  321. Recruiting
    Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06495515

    Age 18 years to 75 years; women only (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  322. Recruiting
    Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06498154

    Age 18 years to 70 years; women only (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  323. Recruiting
    Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06500208

    Age 18 years to 65 years; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  324. Recruiting
    A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-08
    Posted
    Registry
    NCT06503783

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shanghai

  325. Recruiting
    Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06516289

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  326. Recruiting
    Axillary Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With Initial cN1 Breast Cancer
    Phase
    Not given
    Started
    2024-04
    Posted
    Registry
    NCT06518135

    Age 18 years to 70 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  327. Recruiting
    An In-situ Detection for MicroRNA
    Phase
    Not given
    Started
    2024-07
    Posted
    Registry
    NCT06529614

    Age 18 years to 75 years; women only (registered criteria)

    Led by Tongji HospitalWuhan

  328. Recruiting
    A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-08
    Posted
    Registry
    NCT06531486

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  329. Recruiting
    PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC
    Phase
    Phase 3
    Started
    2024-08
    Posted
    Registry
    NCT06533384

    Age 18 years to 70 years; women only (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  330. Recruiting
    Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06534762

    Age 18 years to 65 years (registered criteria)

    Led by Zhejiang Provincial People's HospitalHangzhou

  331. Recruiting
    Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis,an Exploratory, Single-Arm, Multicenter Phase II Clinical Study
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06538896

    Age 18 years to 70 years; women only (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  332. Recruiting
    Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Methotrexate in Breast Cancer With Leptomeningeal Metastasis
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06543992

    Age 18 years to 75 years; women only (registered criteria)

    Led by Jiangsu Province Hospital; 1 listed hospital as study siteNanjing

  333. Recruiting
    A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06555068

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  334. Recruiting
    68Ga FAPI PET/CT Evaluation of Axillary Lymph Node Status After Neoadjuvant Therapy in Patients With Clinical Axillary Lymph Node Positive Breast Cancer
    Phase
    Not given
    Started
    2024-08
    Posted
    Registry
    NCT06559371

    Age 18 years to Not stated; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  335. Recruiting
    Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy
    Phase
    Phase 3
    Started
    2024-07
    Posted
    Registry
    NCT06559696

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  336. Recruiting
    A Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver Metastases
    Phase
    N/A
    Started
    2024-12
    Posted
    Registry
    NCT06567353

    Age 18 years to 75 years; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  337. Recruiting
    Hypofractionated Online Adaptive Radiotherapy of Breast Cancer
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06568705

    Age 35 years to 70 years; women only (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  338. Recruiting
    Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT06587789

    Age 18 years to 80 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  339. Recruiting
    Assessing Combined SBRT in Breast Cancer Non-Responders to Neoadjuvant Chemotherapy
    Phase
    Phase 1/Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06596018

    Age 18 years to 75 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  340. Recruiting
    Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-09
    Posted
    Registry
    NCT06596915

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  341. Recruiting
    A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined With Capecitabine in the Treatment of Active Brain Metastasis of TNBC
    Phase
    Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06598046

    Age 18 years to Not stated; women only (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  342. Recruiting
    Study on the Impact of Electroacupuncture Combined With Self-Acupressure on the Quality of Life of Patients With Early-Stage Breast Cancer Undergoing Chemotherapy
    Phase
    N/A
    Started
    2024-10
    Posted
    Registry
    NCT06601621

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Qinghai UniversityXining

  343. Recruiting
    Electroacupuncture Combined With Self-administered Acupressure for the Prevention of Capecitabine-Associated Hand-Foot Syndrome
    Phase
    N/A
    Started
    2024-10
    Posted
    Registry
    NCT06602167

    Age 18 years to 85 years (registered criteria)

    Led by Affiliated Hospital of Qinghai UniversityXining

  344. Recruiting
    A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-10
    Posted
    Registry
    NCT06609187

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  345. Recruiting
    Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)
    Phase
    Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06611813

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 6 listed hospitals as study sitesHangzhou, Harbin, Hefei, Shanghai, Urumqi, Zhengzhou

  346. Recruiting
    SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC
    Phase
    Phase 3
    Started
    2024-11
    Posted
    Registry
    NCT06627712

    Age 18 years to 65 years; women only (registered criteria)

    Led by West China HospitalChengdu

  347. Recruiting
    AI-Assisted Non-Contrast CT for Multi-Cancer Screening
    Phase
    N/A
    Started
    2024-10
    Posted
    Registry
    NCT06632886

    Age 18 years to Not stated (registered criteria)

    Led by Changhai HospitalShanghai

  348. Recruiting
    All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer:a Multi-center, Multi-cohort Phase II Trial
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06636981

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  349. Recruiting
    The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer
    Phase
    Phase 4
    Started
    2024-10
    Posted
    Registry
    NCT06641544

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  350. Recruiting
    Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06649331

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  351. Recruiting
    Prospective Validation and Application of an Artificial Intelligence-based Model for Evaluating the Efficacy of Breast Cancer Patients After Neoadjuvant Therapy
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT06649565

    Age 18 years to Not stated; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  352. Recruiting
    Drug Sensitivity of Hydrothorax and Ascite Organoids from Breast Cancer
    Phase
    Not given
    Started
    2024-11
    Posted
    Registry
    NCT06658080

    Age 18 years to 70 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteHangzhou

  353. Recruiting
    Large Segmentation Radiotherapy ± Deep Inspiration Breath Hold(DIBH) for Left Breast Cancer
    Phase
    N/A
    Started
    2024-08
    Posted
    Registry
    NCT06660628

    Age 18 years to 70 years; women only (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  354. Recruiting
    Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2024-11
    Posted
    Registry
    NCT06666270

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Zhengzhou

  355. Recruiting
    Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06671262

    Age 18 years to 85 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  356. Recruiting
    A Prospective Cohort Study of Proton and Photon Therapy for Left-sided Breast Cancer.
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06677879

    Age 18 years to 80 years; women only (registered criteria)

    Led by Shanghai Proton and Heavy Ion CenterShanghai

  357. Recruiting
    Arsenous Acid for Refractory Triple-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06678048

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  358. Recruiting
    Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06682195

    Age 18 years to 70 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 10 listed hospitals as study sitesHangzhou, Harbin, Hefei, Nanchang, Shanghai, Taiyuan, Urumqi, Xi'an, Zhengzhou

  359. Recruiting
    The Association of Psychological Stress with the Efficacy of Neoadjuvant Therapy in Breast Cancer
    Phase
    Not given
    Started
    2024-11
    Posted
    Registry
    NCT06690645

    Age 18 years to Not stated; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  360. Recruiting
    Neoadjuvant Chemoradiotherapy Compared to Neoadjuvant Chemotherapy for Luminal-Type Locally Advanced Breast Cancer: A Clinical Study
    Phase
    N/A
    Started
    2024-11
    Posted
    Registry
    NCT06697938

    Age 18 years to 70 years (registered criteria)

    Led by Sichuan Cancer HospitalChengdu

  361. Recruiting
    The Association Between Plasma Metabolites and the Risk, Efficacy and Prognosis in Early Breast Cancer
    Phase
    Not given
    Started
    2024-11
    Posted
    Registry
    NCT06698679

    Age 18 years to Not stated; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  362. Recruiting
    Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06705127

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  363. Recruiting
    Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status
    Phase
    Not given
    Started
    2024-09
    Posted
    Registry
    NCT06713161

    Age 18 years to 75 years; women only (registered criteria)

    Led by Yunnan Cancer HospitalKunming

  364. Recruiting
    Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular Imaging
    Phase
    N/A
    Started
    2024-12
    Posted
    Registry
    NCT06715020

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  365. Recruiting
    Target-specific immunoPET Imaging of Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06715826

    Age 18 years to 75 years; women only (registered criteria)

    Led by Renji HospitalShanghai

  366. Recruiting
    Long-Term Outcomes of Endoscopic-assisted vs Conventional Breast-conserving Surgery in Breast Cancer Patients After Neoadjuvant Therapy: a Randomized, Multicenter, Open Label, Non-inferiority Trial
    Phase
    N/A
    Started
    2024-08
    Posted
    Registry
    NCT06716073

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  367. Recruiting
    The Association Between Age-related Peripheral Blood Components and Treatment Efficacy in Breast Cancer
    Phase
    Not given
    Started
    2024-12
    Posted
    Registry
    NCT06718010

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  368. Recruiting
    Impact of Recombinant Humanized Type III Collagen on the Immediate and Long-term Effects of Breast Tumor Surgery
    Phase
    Phase 1
    Started
    2024-12
    Posted
    Registry
    NCT06725082

    Age 18 years to 80 years; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  369. Recruiting
    GzmB-PET/CT to Evaluate Neoadjuvant Therapy Efficacy in Breast Cancer
    Phase
    Not given
    Started
    2024-11
    Posted
    Registry
    NCT06725940

    Age 18 years to 65 years (registered criteria)

    Led by Ruijin HospitalShanghai

  370. Recruiting
    Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive(HR+) Metastatic Breast Cancer(MBC) .
    Phase
    Not given
    Started
    2024-12
    Posted
    Registry
    NCT06734533

    Age 18 years to 75 years; women only (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  371. Recruiting
    The Optimal Radioimmunotherapy Combinations for Advanced TNBC
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06735131

    Age not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  372. Recruiting
    Hypofractionated Postoperative Regional Nodal Irradiation for Patients With Intermediate-risk Breast Cancer
    Phase
    Phase 3
    Started
    2024-10
    Posted
    Registry
    NCT06757621

    Age 45 years to Not stated; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  373. Recruiting
    The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study
    Phase
    Phase 1
    Started
    2024-11
    Posted
    Registry
    NCT06770296

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province Hospital; 1 listed hospital as study siteNanjing

  374. Recruiting
    Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer.
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06771609

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  375. Recruiting
    Effect of Subanesthetic Dose of Esketamine on Sleep Quality
    Phase
    N/A
    Started
    2024-12
    Posted
    Registry
    NCT06773143

    Age 18 years to 65 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  376. Recruiting
    A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer
    Phase
    Not given
    Started
    2024-09
    Posted
    Registry
    NCT06776861

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  377. Recruiting
    NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.
    Phase
    Not given
    Started
    2024-12
    Posted
    Registry
    NCT06781281

    Age 18 years to Not stated (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  378. Recruiting
    QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06786026

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  379. Recruiting
    Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06817525

    Age 18 years to 65 years; women only (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  380. Recruiting
    Safety and Efficacy of IMPT or IMRT for Breast Cancer
    Phase
    Not given
    Started
    2024-12
    Posted
    Registry
    NCT06826885

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  381. Recruiting
    Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06832904

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  382. Recruiting
    A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06878625

    Age 18 years to 70 years; women only (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  383. Recruiting
    21-gene in Elder Breast Cancer Patients With Lymph Node Metastasis
    Phase
    Not given
    Started
    2024-12
    Posted
    Registry
    NCT06891651

    Age 65 years to Not stated; women only (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  384. Recruiting
    Application of EndoScell Intraoperative Cellular Probing Technology for Early-Stage Breast Cancer
    Phase
    N/A
    Started
    2024-01
    Posted
    Registry
    NCT06911528

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  385. Recruiting
    Observational Clinical Study on Role of MRD in Predicting Local Therapy in Oligometastatic Breast Cancer
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT06918262

    Age not stated (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  386. Recruiting
    Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-01
    Posted
    Registry
    NCT06950086

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  387. Recruiting
    The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study
    Phase
    Phase 2/Phase 3
    Started
    2024-04
    Posted
    Registry
    NCT06958627

    Age 18 years to Not stated; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  388. Recruiting
    Research on the Potential Mechanisms Underlying the Efficacy Differences in Specific Neoadjuvant Treatment Regimens for Different Subtypes of Breast Cancer
    Phase
    N/A
    Started
    2024-04
    Posted
    Registry
    NCT07012720

    Age 25 years to 75 years; women only (registered criteria)

    Led by Xijing HospitalXi'an

  389. Recruiting
    A Study of the Effect of Real-time Pressure Controllers on Subjective and Objective Symptoms of Peripheral Neuropathy Induced by Albumin Paclitaxel
    Phase
    N/A
    Started
    2024-09
    Posted
    Registry
    NCT07019233

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  390. Recruiting
    Evaluation of the Effectiveness and Safety of Laparoscopic Assisted Mastectomy With Preservation of Nipple and Areola, Immediate One-step Breast Reconstruction With Pectoral Muscle Prosthesis and Patch, and Simultaneous Autologous Fat Transplantation
    Phase
    N/A
    Started
    2024-10
    Posted
    Registry
    NCT07037537

    Age 18 years to 70 years; women only (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  391. Recruiting
    PET/CT for Trop2 ADC Response Evaluation Cancers
    Phase
    Not given
    Started
    2024-11
    Posted
    Registry
    NCT07046689

    Age 18 years to Not stated; women only (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  392. Recruiting
    RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
    Phase
    Phase 2
    Started
    2024-01
    Posted
    Registry
    NCT07065435

    Age 18 years to 75 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  393. Recruiting
    Ultra-Hypofractionated vs. Moderately Hypofractionated Proton Therapy for Early Breast Cancer After Lumpectomy
    Phase
    N/A
    Started
    2024-10
    Posted
    Registry
    NCT07135661

    Age 40 years to Not stated; women only (registered criteria)

    Led by Shanghai Proton and Heavy Ion CenterShanghai

  394. Recruiting
    Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study
    Phase
    Not given
    Started
    2024-08
    Posted
    Registry
    NCT07251868

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  395. Recruiting
    ctDNA in HER2+ EBC Neoadjuvant Treatment
    Phase
    Phase 2
    Started
    2024-02
    Posted
    Registry
    NCT07335081

    Age 18 years to 70 years; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  396. Recruiting
    Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
    Phase
    Phase 2
    Started
    2024-01
    Posted
    Registry
    NCT07446452

    Age 18 years to 75 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  397. Recruiting
    Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT07635342

    Age 18 years to 65 years; women only (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  398. Recruiting
    Mecapegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Advanced Breast Cancer
    Phase
    Not given
    Started
    2024-10
    Posted
    Registry
    NCT07899099

    Age 18 years to Not stated (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  399. Recruiting
    A Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Posted
    Registry
    NCT07923214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChengdu, Fuzhou, Shanghai

  400. Recruiting
    Prophylactic Irradiation to the Contralateral Breast for BCAs Patients
    Phase
    N/A
    Started
    2023-01
    Posted
    Registry
    NCT04960839

    Age 30 years to 70 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 5 listed hospitals as study sitesHangzhou, Nanchang, Shanghai

  401. Recruiting
    Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks
    Phase
    Phase 3
    Started
    2023-03
    Posted
    Registry
    NCT05212454

    Age 18 years to 70 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  402. Recruiting
    Impact of Erector Spinae Plane Block on Chronic Postsurgical Pain in Breast Cancer Patients
    Phase
    N/A
    Started
    2023-05
    Posted
    Registry
    NCT05494502

    Age 18 years to 85 years (registered criteria)

    Led by Peking University First Hospital; 1 listed hospital as study siteBeijing

  403. Recruiting
    UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases
    Phase
    Phase 1/Phase 2
    Started
    2023-01
    Posted
    Registry
    NCT05535413

    Age 18 years to 70 years; women only (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  404. Recruiting
    A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
    Phase
    Phase 2
    Started
    2023-03
    Posted
    Registry
    NCT05635487

    Age 18 years to 75 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  405. Recruiting
    A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05646862

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Tianjin, Wuhan

  406. Recruiting
    A Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Breast Cancer With Implantation Reconstruction
    Phase
    Phase 2
    Started
    2023-01
    Posted
    Registry
    NCT05692674

    Age 18 years to 80 years; women only (registered criteria)

    Led by Shanghai Proton and Heavy Ion CenterShanghai

  407. Recruiting
    Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
    Phase
    Phase 3
    Started
    2023-10
    Posted
    Registry
    NCT05696626

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 57 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  408. Recruiting
    PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients
    Phase
    Phase 2
    Started
    2023-03
    Posted
    Registry
    NCT05704166

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  409. Recruiting
    Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2023-04
    Posted
    Registry
    NCT05744687

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesAnyang, Beijing, Changchun, Fuzhou, Guangzhou, Luoyang, Yinchuan

  410. Recruiting
    FUSCC Refractory TNBC Platform Study (FUTURE2.0)
    Phase
    Phase 2
    Started
    2023-03
    Posted
    Registry
    NCT05749588

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  411. Recruiting
    PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2023-02
    Posted
    Registry
    NCT05759546

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  412. Recruiting
    Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
    Phase
    Phase 3
    Started
    2023-03
    Posted
    Registry
    NCT05760378

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  413. Recruiting
    Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
    Phase
    Phase 3
    Started
    2023-03
    Posted
    Registry
    NCT05760612

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  414. Recruiting
    Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
    Phase
    Phase 2
    Started
    2023-03
    Posted
    Registry
    NCT05769010

    Age 18 years to 75 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  415. Recruiting
    CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer
    Phase
    Not given
    Started
    2023-04
    Posted
    Registry
    NCT05795335

    Age 18 years to Not stated (registered criteria)

    Led by Renji HospitalShanghai

  416. Recruiting
    Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2023-04
    Posted
    Registry
    NCT05806060

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  417. Recruiting
    RC48-ADC in HER2-low Advanced Breast Cancer
    Phase
    N/A
    Started
    2023-05
    Posted
    Registry
    NCT05831878

    Age 18 years to Not stated; women only (registered criteria)

    Led by Renji HospitalShanghai

  418. Recruiting
    Pyrotinib in Women With High-risk in Early Stage Breast Cancer
    Phase
    Phase 2
    Started
    2023-04
    Posted
    Registry
    NCT05834764

    Age 18 years to 75 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  419. Recruiting
    Integrin αvβ6-targeted PET in Malignant Tumors
    Phase
    Not given
    Started
    2023-01
    Posted
    Registry
    NCT05835570

    Age 18 years to 85 years (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

  420. Recruiting
    Disitamab Vedotin (RC48-ADC) in Breast Cancer
    Phase
    Not given
    Started
    2023-06
    Posted
    Registry
    NCT05851677

    Age not stated (registered criteria)

    Led by Renji HospitalShanghai

  421. Recruiting
    Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2023-09
    Posted
    Registry
    NCT05860465

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanjing, Shenyang, Shijiazhuang, Tianjin, Xi'an, Yinchuan

  422. Recruiting
    Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer
    Phase
    Phase 2
    Started
    2023-06
    Posted
    Registry
    NCT05861271

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  423. Recruiting
    A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05862064

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  424. Recruiting
    Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
    Phase
    Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT05872347

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Guangzhou, Hangzhou, Harbin, Hefei, Luoyang, Nanjing, Nanning, Shijiazhuang, Tianjin, Urumqi, Wuhan, Xiangyang, Yinchuan, Zhengzhou

  425. Recruiting
    Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
    Phase
    N/A
    Started
    2023-06
    Posted
    Registry
    NCT05876065

    Age 18 years to Not stated; women only (registered criteria)

    Led by Renji HospitalShanghai

  426. Recruiting
    EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05883852

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  427. Recruiting
    Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05891093

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 13 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nantong, Ningbo, Shanghai, Shenyang, Xi'an, Yangzhou

  428. Recruiting
    Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT05891561

    Age 18 years to 75 years; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  429. Recruiting
    A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2023-09
    Posted
    Registry
    NCT05894239

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Fuzhou, Hangzhou, Jinan, Luoyang, Nanchang, Nanning, Shijiazhuang, Tianjin, Wuhan

  430. Recruiting
    TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05901428

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  431. Recruiting
    Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)
    Phase
    Phase 3
    Started
    2023-07
    Posted
    Registry
    NCT05904964

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 1 listed hospital as study siteGuangzhou, Shantou

  432. Recruiting
    Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05909332

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 13 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nantong, Ningbo, Shanghai, Shenyang, Xi'an, Yangzhou

  433. Recruiting
    Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05910398

    Age 18 years to Not stated (registered criteria)

    Led by Renji HospitalShanghai

  434. Recruiting
    A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer
    Phase
    Phase 2
    Started
    2023-07
    Posted
    Registry
    NCT05911958

    Age 18 years to 70 years; women only (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  435. Recruiting
    Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC
    Phase
    Phase 2
    Started
    2023-05
    Posted
    Registry
    NCT05918328

    Age 18 years to 65 years; women only (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  436. Recruiting
    Omission of SLNB in CN0 Early Breast Cancer
    Phase
    N/A
    Started
    2023-06
    Posted
    Registry
    NCT05935150

    Age 18 years to 70 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  437. Recruiting
    Omission of ALND in Breast Cancer Patients With Axillary pCR
    Phase
    N/A
    Started
    2023-09
    Posted
    Registry
    NCT05939830

    Age 18 years to 70 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  438. Recruiting
    Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2023-07
    Posted
    Registry
    NCT05949541

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  439. Recruiting
    Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT05950945

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang, Qingdao, Shanghai, Xi'an, Zhengzhou

  440. Recruiting
    Regional Lymph Node Irradiation for High-risk pN0 Breast Cancer
    Phase
    N/A
    Started
    2023-07
    Posted
    Registry
    NCT05976412

    Age 18 years to Not stated; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  441. Recruiting
    Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2023-08
    Posted
    Registry
    NCT05981001

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  442. Recruiting
    Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2023-08
    Posted
    Registry
    NCT05981014

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  443. Recruiting
    Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2023-07
    Posted
    Registry
    NCT05983107

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  444. Recruiting
    A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
    Phase
    Phase 3
    Started
    2023-08
    Posted
    Registry
    NCT05999149

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  445. Recruiting
    A Study of Neoadjuvant TCHpy(Pyrotinib ,Trastuzumab,Carboplatin and Paclitaxel)for ER+/HER2+ Breast Cancer
    Phase
    Phase 2
    Started
    2023-05
    Posted
    Registry
    NCT06000917

    Age 18 years to 75 years; women only (registered criteria)

    Led by Union HospitalWuhan

  446. Recruiting
    A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06001086

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 1 listed hospital as study siteNanjing

  447. Recruiting
    Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.
    Phase
    Not given
    Started
    2023-01
    Posted
    Registry
    NCT06033287

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  448. Recruiting
    Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer
    Phase
    Not given
    Started
    2023-06
    Posted
    Registry
    NCT06035016

    Age 18 years to 75 years; women only (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  449. Recruiting
    Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer
    Phase
    N/A
    Started
    2023-08
    Posted
    Registry
    NCT06035679

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Affiliated Hospital of Fujan Medical University

  450. Recruiting
    A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06042894

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  451. Recruiting
    A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
    Phase
    Phase 1
    Started
    2023-08
    Posted
    Registry
    NCT06043466

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou

  452. Recruiting
    A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
    Phase
    Phase 1/Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT06064812

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesChangchun, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

  453. Recruiting
    JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06079983

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 60 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hengyang, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Meizhou, Nanchang, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xining, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

  454. Recruiting
    Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
    Phase
    Phase 3
    Started
    2023-10
    Posted
    Registry
    NCT06081959

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  455. Recruiting
    99mTc-MY6349 SPECT/CT Imaging in Trop2-positive Triple-negative Breast Cancer
    Phase
    N/A
    Started
    2023-09
    Posted
    Registry
    NCT06104085

    Age 18 years to 80 years; women only (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  456. Recruiting
    Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer (EBC)
    Phase
    Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT06107673

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  457. Recruiting
    A Study of YL202 in Selected Patients With Advanced Solid Tumors
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06107686

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jinan, Meizhou, Nanchang, Nanning, Qingdao, Shanghai, Shantou, Shenyang, Suzhou, Taiyuan, Taizhou, Urumqi, Weifang, Wuhan, Xi'an, Xiangyang, Xuzhou, Zhengzhou

  458. Recruiting
    BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2023-12
    Posted
    Registry
    NCT06120283

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shanghai, Shenyang

  459. Recruiting
    Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
    Phase
    Phase 1
    Started
    2023-11
    Posted
    Registry
    NCT06121557

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  460. Recruiting
    Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
    Phase
    Phase 1
    Started
    2023-11
    Posted
    Registry
    NCT06121570

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  461. Recruiting
    Organoids Based Drug Sensitivity in Neoadjuvant Chemotherapy of Breast Cancer
    Phase
    Not given
    Started
    2023-12
    Posted
    Registry
    NCT06155305

    Age 18 years to 70 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  462. Recruiting
    Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC
    Phase
    Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT06165900

    Age 18 years to 75 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  463. Recruiting
    Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06167694

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Guangzhou

  464. Recruiting
    DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06178159

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  465. Recruiting
    Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06199895

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  466. Recruiting
    Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
    Phase
    Phase 2
    Started
    2023-07
    Posted
    Registry
    NCT06227117

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChangsha, Hangzhou, Shanghai, Tianjin

  467. Recruiting
    Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
    Phase
    Phase 3
    Started
    2023-09
    Posted
    Registry
    NCT06278870

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  468. Recruiting
    AI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes Tumors
    Phase
    Not given
    Started
    2023-03
    Posted
    Registry
    NCT06286267

    Age not stated; women only (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 1 listed hospital as study siteGuangzhou

  469. Recruiting
    Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06341894

    Age 18 years to 75 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  470. Recruiting
    Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing
    Phase
    Not given
    Started
    2023-08
    Posted
    Registry
    NCT06413212

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  471. Recruiting
    a Single-arm, Single-center, Open Clinical Study
    Phase
    Not given
    Started
    2023-07
    Posted
    Registry
    NCT06431100

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  472. Recruiting
    A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2023-04
    Posted
    Registry
    NCT06508307

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  473. Recruiting
    To Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer Patients
    Phase
    Not given
    Started
    2023-04
    Posted
    Registry
    NCT06605521

    Age 18 years to 80 years; women only (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  474. Recruiting
    Photoacoustic/Ultrasound Imaging for Breast Nodule Diagnosis, Molecular Classification, and Neoadjuvant Chemotherapy Response Evaluation
    Phase
    N/A
    Started
    2023-06
    Posted
    Registry
    NCT06908291

    Age 18 years to Not stated; women only (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  475. Recruiting
    Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2023-02
    Posted
    Registry
    NCT07014410

    Age 18 years to 75 years; women only (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  476. Recruiting
    Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
    Phase
    Not given
    Started
    2023-01
    Posted
    Registry
    NCT07073755

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  477. Recruiting
    The Efficacy of Compression/Ice Gloves/Socks in Patients With UTD1-induced Neuropathy.
    Phase
    N/A
    Started
    2023-03
    Posted
    Registry
    NCT07638774

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  478. Recruiting
    Comparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery (SRRSHzb-EABCS) With Those of Conventional Breast-Conserving Surgery
    Phase
    N/A
    Started
    2023-07
    Posted
    Registry
    NCT07920094

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sir Run Run Shaw Hospital; 10 listed hospitals as study sitesHangzhou, Jinhua, Ningbo, Taizhou, Wenzhou

  479. Recruiting
    Reverse Triple Negative Immune Resistant Breast Cancer
    Phase
    Phase 2
    Started
    2022-06
    Posted
    Registry
    NCT05076682

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  480. Recruiting
    Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC
    Phase
    Phase 2
    Started
    2022-01
    Posted
    Registry
    NCT05192798

    Age 18 years to 80 years; women only (registered criteria)

    Led by First Affiliated Hospital of Bengbu Medical UniversityBengbu

  481. Recruiting
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2022-10
    Posted
    Registry
    NCT05208762

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  482. Recruiting
    Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC
    Phase
    Phase 2
    Started
    2022-02
    Posted
    Registry
    NCT05228951

    Age 18 years to 75 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  483. Recruiting
    The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.
    Phase
    Not given
    Started
    2022-08
    Posted
    Registry
    NCT05263570

    Age 18 years to Not stated; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  484. Recruiting
    Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2022-03
    Posted
    Registry
    NCT05296577

    Age 18 years to Not stated; women only (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  485. Recruiting
    Assessment of Brain Cognitive Impairment in Breast Cancer
    Phase
    Not given
    Started
    2022-05
    Posted
    Registry
    NCT05305092

    Age not stated; women only (registered criteria)

    Led by Tangdu HospitalXi'an

  486. Recruiting
    Effectiveness of Cryotherapy Combined With Compression Therapy for Preventing Chemotherapy-induced Peripheral Neuropathy
    Phase
    N/A
    Started
    2022-06
    Posted
    Registry
    NCT05341141

    Age 20 years to 70 years; women only (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  487. Recruiting
    EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer
    Phase
    Early phase 1
    Started
    2022-05
    Posted
    Registry
    NCT05341492

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  488. Recruiting
    Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer
    Phase
    N/A
    Started
    2022-03
    Posted
    Registry
    NCT05345860

    Age 18 years to Not stated; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  489. Recruiting
    Prone Positioning CT Scan and Ultrasound Assessing Axillary Lymph Nodes in Patients With Breast Cancer Official Title: Evaluation of Axillary Lymph Nodes Using Prone Positioning Computed Tomography Scan and Ultrasound in Patients With Breast Cancer
    Phase
    N/A
    Started
    2022-03
    Posted
    Registry
    NCT05346510

    Age 18 years to 70 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  490. Recruiting
    CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial
    Phase
    N/A
    Started
    2022-09
    Posted
    Registry
    NCT05360290

    Age 18 years to 70 years; women only (registered criteria)

    Led by Renji HospitalShanghai

  491. Recruiting
    Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2022-08
    Posted
    Registry
    NCT05398861

    Age 18 years to 70 years; women only (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  492. Recruiting
    A Study for the Neoadjuvant Treatment of Breast Cancer
    Phase
    Phase 4
    Started
    2022-07
    Posted
    Registry
    NCT05420454

    Age 18 years to Not stated; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  493. Recruiting
    A Study for the Adjuvant Treatment of Breast Cancer
    Phase
    Phase 4
    Started
    2022-07
    Posted
    Registry
    NCT05420467

    Age 18 years to Not stated; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  494. Recruiting
    Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2022-06
    Posted
    Registry
    NCT05430399

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangsha

  495. Recruiting
    Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
    Phase
    Phase 2
    Started
    2022-11
    Posted
    Registry
    NCT05447702

    Age 18 years to 75 years; women only (registered criteria)

    Led by West China HospitalChengdu

  496. Recruiting
    A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2022-08
    Posted
    Registry
    NCT05461768

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Guangzhou, Jinan, Wuhan, Zhengzhou

  497. Recruiting
    A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2022-08
    Posted
    Registry
    NCT05470348

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai

  498. Recruiting
    Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer
    Phase
    Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05475678

    Age 18 years to 70 years; women only (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  499. Recruiting
    JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05490472

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Changchun, Jinan

  500. Recruiting
    Patient-Reported Outcome and Safety Between Preoperative and Postmastectomy Radiotherapy in DIEP Flap Reconstruction
    Phase
    N/A
    Started
    2022-08
    Posted
    Registry
    NCT05512286

    Age 18 years to Not stated; women only (registered criteria)

    Led by Huashan Hospital; 2 listed hospitals as study sitesChangsha, Shanghai, Zhengzhou

  501. Recruiting
    Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer
    Phase
    Phase 4
    Started
    2022-03
    Posted
    Registry
    NCT05525767

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  502. Recruiting
    68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients
    Phase
    Early phase 1
    Started
    2022-08
    Posted
    Registry
    NCT05549024

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  503. Recruiting
    GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2022-10
    Posted
    Registry
    NCT05575804

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  504. Recruiting
    Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study
    Phase
    Phase 2
    Started
    2022-10
    Posted
    Registry
    NCT05576389

    Age 18 years to Not stated; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  505. Recruiting
    Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05579366

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan

  506. Recruiting
    Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
    Phase
    Phase 2
    Started
    2022-11
    Posted
    Registry
    NCT05582499

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  507. Recruiting
    SNF Platform Study of HR+/ HER2-advanced Breast Cancer
    Phase
    Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05594095

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  508. Recruiting
    A Prospective Study of Preoperative Tumor-bed Boost Followed by Oncoplastic Surgery and Adjuvant Whole Breast Radiotherapy for Early Stage Breast Cancer (BIRKIN)
    Phase
    N/A
    Started
    2022-06
    Posted
    Registry
    NCT05603078

    Age Not stated to 55 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  509. Recruiting
    Pre-operative Therapy in Breast Cancer
    Phase
    Not given
    Started
    2022-11
    Posted
    Registry
    NCT05621564

    Age 18 years to Not stated; women only (registered criteria)

    Led by Renji HospitalShanghai

  510. Recruiting
    Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
    Phase
    Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05638594

    Age 18 years to 75 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  511. Recruiting
    Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen
    Phase
    Not given
    Started
    2022-05
    Posted
    Registry
    NCT05731258

    Age 18 years to 75 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  512. Recruiting
    Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation
    Phase
    Phase 2
    Started
    2022-05
    Posted
    Registry
    NCT05761470

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  513. Recruiting
    Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients
    Phase
    Phase 2
    Started
    2022-10
    Posted
    Registry
    NCT05762900

    Age 35 years to Not stated; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  514. Recruiting
    Optical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2022-04
    Posted
    Registry
    NCT05804916

    Age 18 years to 70 years; women only (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  515. Recruiting
    Comparison Between Prepectoral and Subpectoral Breast Reconstruction
    Phase
    Not given
    Started
    2022-03
    Posted
    Registry
    NCT05833659

    Age 18 years to 70 years; women only (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  516. Recruiting
    A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2022-01
    Posted
    Registry
    NCT05851014

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an, Yinchuan, Zhengzhou

  517. Recruiting
    Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC
    Phase
    Not given
    Started
    2022-03
    Posted
    Registry
    NCT05856383

    Age 18 years to Not stated (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  518. Recruiting
    Cold Dissection Versus Electrocautery Dissection in Endoscopic Nipple-Sparing Mastectomy and Immediate Implant-Based Reconstruction: A Randomized Controlled Trial
    Phase
    N/A
    Started
    2022-11
    Posted
    Registry
    NCT06024187

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  519. Recruiting
    A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2022-01
    Posted
    Registry
    NCT06313983

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  520. Recruiting
    Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
    Phase
    Not given
    Started
    2022-10
    Posted
    Registry
    NCT06551220

    Age 18 years to 80 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Foshan, Fuzhou, Guangzhou, Hangzhou, Hengyang, Nanjing, Shanghai, Shantou, Shenzhen, Zhuhai

  521. Recruiting
    Super-Hypofractionated Partial Breast Irradiation
    Phase
    N/A
    Started
    2022-04
    Posted
    Registry
    NCT06615466

    Age 45 years to 74 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  522. Recruiting
    A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2022-09
    Posted
    Registry
    NCT06954961

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Harbin

  523. Recruiting
    Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy
    Phase
    Phase 3
    Started
    2022-06
    Posted
    Registry
    NCT06998108

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  524. Recruiting
    Regional Radiotherapy Omission in Low-Risk Node Positive Breast Cancer
    Phase
    Not given
    Started
    2022-07
    Posted
    Registry
    NCT07179744

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  525. Recruiting
    Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
    Phase
    Phase 4
    Started
    2021-07
    Posted
    Registry
    NCT04136782

    Age 18 years to 70 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical University; 3 listed hospitals as study sitesChangchun, Harbin, Shenyang

  526. Recruiting
    Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT
    Phase
    Phase 3
    Started
    2021-07
    Posted
    Registry
    NCT04137653

    Age 18 years to 70 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  527. Recruiting
    Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy
    Phase
    Not given
    Started
    2021-07
    Posted
    Registry
    NCT04476485

    Age 18 years to 70 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical University; 3 listed hospitals as study sitesChangchun, Harbin, Shenyang

  528. Recruiting
    Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer
    Phase
    N/A
    Started
    2021-03
    Posted
    Registry
    NCT04517266

    Age 18 years to 80 years; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  529. Recruiting
    Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer
    Phase
    Phase 3
    Started
    2021-04
    Posted
    Registry
    NCT04722978

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  530. Recruiting
    Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients
    Phase
    Phase 1/Phase 2
    Started
    2021-03
    Posted
    Registry
    NCT04750122

    Age 18 years to 75 years; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  531. Recruiting
    Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
    Phase
    Phase 4
    Started
    2021-06
    Posted
    Registry
    NCT04790305

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Wuhan, Xi'an, Yangzhou, Zhengzhou

  532. Recruiting
    A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC
    Phase
    Phase 2/Phase 3
    Started
    2021-04
    Posted
    Registry
    NCT04803539

    Age 18 years to 80 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  533. Recruiting
    Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients
    Phase
    Phase 1/Phase 2
    Started
    2021-04
    Posted
    Registry
    NCT04836156

    Age 18 years to 75 years; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  534. Recruiting
    Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2021-01
    Posted
    Registry
    NCT04842812

    Age 18 years to 85 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  535. Recruiting
    Single Arm Phase II Study of Fractionated Stereotatic Radiation Therapy (FSRT) for Bone Metastases in Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2021-01
    Posted
    Registry
    NCT04947280

    Age not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  536. Recruiting
    Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients
    Phase
    Phase 2
    Started
    2021-08
    Posted
    Registry
    NCT04983121

    Age 18 years to 75 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  537. Recruiting
    The Association Between Radiation Dermatitis and Skin Microbiome in Breast Cancer Patients
    Phase
    Not given
    Started
    2021-01
    Posted
    Registry
    NCT05032768

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  538. Recruiting
    Medial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast Cancer
    Phase
    Phase 3
    Started
    2021-09
    Posted
    Registry
    NCT05059379

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  539. Recruiting
    Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer
    Phase
    Phase 3
    Started
    2021-09
    Posted
    Registry
    NCT05063136

    Age 18 years to 70 years; women only (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  540. Recruiting
    A Study of GC101 TIL in Advanced Breast Cancer (10hospital)
    Phase
    Early phase 1
    Started
    2021-11
    Posted
    Registry
    NCT05142475

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  541. Recruiting
    Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
    Phase
    Phase 3
    Started
    2021-12
    Posted
    Registry
    NCT05159193

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  542. Recruiting
    Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Posted
    Registry
    NCT05187338

    Age 18 years to 70 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  543. Recruiting
    Axillary Lymph Node Treatment Guided by Naocarbon Tracing After Neoadjuvant Chemotherapy
    Phase
    N/A
    Started
    2021-11
    Posted
    Registry
    NCT05241119

    Age 18 years to 70 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical University; 1 listed hospital as study siteShenyang

  544. Recruiting
    Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer
    Phase
    Phase 2
    Started
    2021-07
    Posted
    Registry
    NCT05292742

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fujian Medical University Union HospitalFuzhou

  545. Recruiting
    Neoadjuvant Radiation in Locally Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2021-03
    Posted
    Registry
    NCT05479409

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  546. Recruiting
    Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer
    Phase
    Not given
    Started
    2021-12
    Posted
    Registry
    NCT05541367

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  547. Recruiting
    Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index
    Phase
    Phase 2
    Started
    2021-08
    Posted
    Registry
    NCT05728268

    Age 18 years to 70 years; women only (registered criteria)

    Led by Shantou Central HospitalShantou

  548. Recruiting
    A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer
    Phase
    N/A
    Started
    2021-11
    Posted
    Registry
    NCT06234137

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou

  549. Recruiting
    Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC
    Phase
    Not given
    Started
    2021-06
    Posted
    Registry
    NCT06754059

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fujian Union Medical College HospitalFuzhou

  550. Recruiting
    Application of CT-Linac-Based "All-in-One" One-Stop Radiotherapy in Breast Cancer
    Phase
    N/A
    Started
    2021-08
    Posted
    Registry
    NCT07776301

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  551. Recruiting
    Radical Local vs. Palliative Therapy for Breast Cancer Patientts With Ipsilateral Humerus or Sternum Oligometastasis
    Phase
    N/A
    Started
    2020-05
    Posted
    Registry
    NCT04158843

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou

  552. Recruiting
    Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer
    Phase
    N/A
    Started
    2020-04
    Posted
    Registry
    NCT04281641

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  553. Recruiting
    Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
    Phase
    Phase 2
    Started
    2020-07
    Posted
    Registry
    NCT04481932

    Age 18 years to 70 years; women only (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  554. Recruiting
    A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC
    Phase
    Phase 2
    Started
    2020-08
    Posted
    Registry
    NCT04501523

    Age 18 years to 80 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  555. Recruiting
    Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
    Phase
    Phase 2
    Started
    2020-09
    Posted
    Registry
    NCT04557449

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Wuhan, Xi'an, Zhengzhou

  556. Recruiting
    Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2020-09
    Posted
    Registry
    NCT04576143

    Age 18 years to 70 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  557. Recruiting
    Study of PF-07248144 in Advanced or Metastatic Solid Tumors
    Phase
    Phase 2
    Started
    2020-11
    Posted
    Registry
    NCT04606446

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Xi'an

  558. Recruiting
    Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2020-10
    Posted
    Registry
    NCT04646759

    Age 18 years to 80 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  559. Recruiting
    Nomogram to Predict Breast Cancer Related Lymphedema
    Phase
    N/A
    Started
    2020-12
    Posted
    Registry
    NCT04665882

    Age 18 years to 80 years; women only (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

  560. Recruiting
    Selective Omission of Axillary Surgery in Triple-negative and HER2-positive Breast Cancer After NACT
    Phase
    N/A
    Started
    2020-07
    Posted
    Registry
    NCT05314114

    Age 18 years to 70 years; women only (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  561. Recruiting
    Clinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast Cancer
    Phase
    Not given
    Started
    2020-11
    Posted
    Registry
    NCT06375798

    Age 55 years to Not stated; women only (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  562. Recruiting
    Hypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard Treatment
    Phase
    Phase 3
    Started
    2019-02
    Posted
    Registry
    NCT03829553

    Age 18 years to 75 years; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  563. Recruiting
    Circulating Tumor Cell Detection in Patients With Luminal A Breast Cancer
    Phase
    Not given
    Started
    2019-10
    Posted
    Registry
    NCT04065321

    Age 18 years to 60 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical University; 1 listed hospital as study siteShenyang

  564. Recruiting
    RecurIndex Guided Avoidance of Regional Nodal Irradiation for Node Positive Breast Cancer
    Phase
    N/A
    Started
    2019-08
    Posted
    Registry
    NCT04069884

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  565. Recruiting
    Sentinel Node Biopsy Vs Observation After Axillary PET
    Phase
    N/A
    Started
    2019-09
    Posted
    Registry
    NCT04072653

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  566. Recruiting
    Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
    Phase
    Phase 2
    Started
    2019-11
    Posted
    Registry
    NCT04138719

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  567. Recruiting
    Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer
    Phase
    Phase 2
    Started
    2019-11
    Posted
    Registry
    NCT04159142

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  568. Recruiting
    Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
    Phase
    Phase 3
    Started
    2019-12
    Posted
    Registry
    NCT04254263

    Age 18 years to 70 years; women only (registered criteria)

    Led by Renji HospitalShanghai

  569. Recruiting
    Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients
    Phase
    Not given
    Started
    2019-03
    Posted
    Registry
    NCT05326295

    Age 18 years to 75 years; women only (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  570. Recruiting
    De-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC
    Phase
    Not given
    Started
    2019-01
    Posted
    Registry
    NCT06692725

    Age not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  571. Recruiting
    Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer
    Phase
    Not given
    Started
    2019-01
    Posted
    Registry
    NCT06693024

    Age not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  572. Recruiting
    Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy
    Phase
    Not given
    Started
    2019-01
    Posted
    Registry
    NCT06693037

    Age not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  573. Recruiting
    Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC
    Phase
    Not given
    Started
    2019-01
    Posted
    Registry
    NCT06700382

    Age not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  574. Recruiting
    Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy
    Phase
    Not given
    Started
    2019-01
    Posted
    Registry
    NCT06711068

    Age not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  575. Recruiting
    Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients
    Phase
    Not given
    Started
    2019-01
    Posted
    Registry
    NCT06722599

    Age not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  576. Recruiting
    Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer
    Phase
    Not given
    Started
    2019-01
    Posted
    Registry
    NCT06722612

    Age not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  577. Recruiting
    Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
    Phase
    Phase 2/Phase 3
    Started
    2018-11
    Posted
    Registry
    NCT03755739

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  578. Recruiting
    Hypofractionated Vs Conventional Fractionated Radiotherapy After Breast Conserving Surgery
    Phase
    N/A
    Started
    2018-07
    Posted
    Registry
    NCT04025164

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 2 listed hospitals as study sitesDalian, Guiyang, Shanghai

  579. Recruiting
    Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2018-05
    Posted
    Registry
    NCT04263298

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChangsha, Guangzhou, Nanning, Shantou, Shenzhen, Zhanjiang

  580. Recruiting
    Application of Radiomics in Breast Cancer
    Phase
    Not given
    Started
    2018-01
    Posted
    Registry
    NCT04483804

    Age 18 years to 80 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  581. Recruiting
    Evaluation of Thyroid Abnormity Incidence and Thyroid Toxicity During Chemotherapy Among Newly Diagnosed Breast Cancer
    Phase
    Not given
    Started
    2017-06
    Posted
    Registry
    NCT03177902

    Age 18 years to 85 years; women only (registered criteria)

    Led by First Affiliated Hospital of Bengbu Medical UniversityBengbu

  582. Recruiting
    Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women
    Phase
    Phase 3
    Started
    2017-07
    Posted
    Registry
    NCT03201861

    Age 18 years to 70 years; women only (registered criteria)

    Led by Renji HospitalShanghai

  583. Recruiting
    Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors
    Phase
    Phase 2
    Started
    2017-08
    Posted
    Registry
    NCT03392233

    Age 18 years to 85 years (registered criteria)

    Led by Renji HospitalShanghai

  584. Recruiting
    Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer
    Phase
    Phase 3
    Started
    2015-07
    Posted
    Registry
    NCT02535221

    Age 35 years to 55 years; women only (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  585. Recruiting
    De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients
    Phase
    Not given
    Started
    2015-01
    Posted
    Registry
    NCT06700369

    Age not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  586. Recruiting
    Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer
    Phase
    Not given
    Started
    2015-01
    Posted
    Registry
    NCT06711055

    Age not stated; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  587. Recruiting
    A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast
    Phase
    Phase 1
    Started
    2013-01
    Posted
    Registry
    NCT02897700

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangchun, Shanghai

  588. Not yet recruiting
    Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer
    Phase
    Phase 2
    Started
    2027-01
    Posted
    Registry
    NCT07419880

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  589. Not yet recruiting
    ADC Based Therapy Accroding to HER2 Heterogeneous
    Phase
    Phase 2
    Started
    2027-01
    Posted
    Registry
    NCT07844018

    Age 18 years to Not stated; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  590. Not yet recruiting
    A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07235618

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  591. Not yet recruiting
    Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)
    Phase
    Phase 2
    Started
    2026-11
    Posted
    Registry
    NCT07255612

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  592. Not yet recruiting
    A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positive Breast Cancer
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07294339

    Age 18 years to 75 years; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  593. Not yet recruiting
    Cellular-Level Fluorescence Imaging for Intraoperative Margin Assessment in Breast Cancer
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07311317

    Age 18 years to 70 years; women only (registered criteria)

    Led by West China Hospital; 1 listed hospital as study siteChengdu

  594. Not yet recruiting
    Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07317778

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  595. Not yet recruiting
    JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07336771

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  596. Not yet recruiting
    Huaier Granule and Proteinuria
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07355361

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  597. Not yet recruiting
    Effect of Esketamine on Perioperative Negative Emotions in Patients Undergoing Breast Cancer Surgery
    Phase
    N/A
    Started
    2026-01
    Posted
    Registry
    NCT07367542

    Age 18 years to Not stated; women only (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  598. Not yet recruiting
    Efficacy and Safety of Qibei Jiedu Formula for Preventing and Managing Acute Radiation Dermatitis in Breast Cancer Patients
    Phase
    N/A
    Started
    2026-01
    Posted
    Registry
    NCT07380230

    Age 18 years to Not stated; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  599. Not yet recruiting
    Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype
    Phase
    Phase 3
    Started
    2026-02
    Posted
    Registry
    NCT07382687

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  600. Not yet recruiting
    Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07410559

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  601. Not yet recruiting
    Pedicled Lateral Chest Wall Lymph-Adipofascial Flap to Prevent Arm Lymphedema After Breast Cancer Surgery
    Phase
    N/A
    Started
    2026-02
    Posted
    Registry
    NCT07415200

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  602. Not yet recruiting
    A Platform Study Based on Specific Tracer for Evaluating the Therapeutic Efficacy of Systemic Treatment for Breast Cancer Using PET/MRI
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07419867

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  603. Not yet recruiting
    ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07423611

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  604. Not yet recruiting
    Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Perioperative Negative Emotions in Breast Cancer Surgery Patients
    Phase
    N/A
    Started
    2026-02
    Posted
    Registry
    NCT07458646

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  605. Not yet recruiting
    Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07466303

    Age 18 years to 70 years; women only (registered criteria)

    Led by Xijing HospitalXi'an

  606. Not yet recruiting
    Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07466927

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  607. Not yet recruiting
    Effect of Acupuncture on Psychoneurological Symptom Cluster in Breast Cancer Survivors
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07481903

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Teaching Hospital, Tianjin University of Traditional Chinese Medicine; 3 listed hospitals as study sitesBeijing, Nanjing, Tianjin

  608. Not yet recruiting
    Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07487519

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHarbin

  609. Not yet recruiting
    Decision Aid for Women Newly Diagnosed With Breast Cancer
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07497256

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesXiamen

  610. Not yet recruiting
    Baduanjin Exercise on Upper Limb Dysfunction Among Breast Cancer Survivors
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07522593

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZunyi

  611. Not yet recruiting
    Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC
    Phase
    Not given
    Started
    2026-05
    Posted
    Registry
    NCT07523789

    Age 18 years to Not stated; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  612. Not yet recruiting
    Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07528898

    Age 18 years to 70 years (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  613. Not yet recruiting
    Effects of Instrument-Assisted Constant-Speed Injection Versus Manual Injection on Pain From Large-Volume Subcutaneous Injection of Pertuzumab and Trastuzumab in Breast Cancer: A Randomized, Self-Controlled Study
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07533526

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  614. Not yet recruiting
    Proton vs Photon IMRT Toxicity in Breast Cancer
    Phase
    Not given
    Started
    2026-04
    Posted
    Registry
    NCT07537712

    Age 18 years to Not stated; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  615. Not yet recruiting
    The Comparison Between M-E-BCS and C-O-BCS.
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07539545

    Age 18 years to 70 years; women only (registered criteria)

    Led by West China HospitalChengdu

  616. Not yet recruiting
    Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07539753

    Age 18 years to 75 years; women only (registered criteria)

    Led by Nanfang HospitalGuangzhou

  617. Not yet recruiting
    Areola Preservation in NSM With Nipple Involvement
    Phase
    N/A
    Started
    2026-05
    Posted
    Registry
    NCT07544134

    Age 18 years to Not stated; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  618. Not yet recruiting
    A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07556848

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  619. Not yet recruiting
    A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07560124

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Harbin

  620. Not yet recruiting
    Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07560475

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  621. Not yet recruiting
    5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors
    Phase
    N/A
    Started
    2026-06
    Posted
    Registry
    NCT07589101

    Age 18 years to 70 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  622. Not yet recruiting
    Clinical Application of Vagus Nerve Stimulation Combined With Immunoregulatory T Cells in Alleviating Aromatase Inhibitor-Induced Pain
    Phase
    N/A
    Started
    2026-05
    Posted
    Registry
    NCT07593365

    Age 18 years to Not stated; women only (registered criteria)

    Led by Peking University People's HospitalBeijing

  623. Not yet recruiting
    The Comparison Between DEDTI BR and T/E BR
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07593846

    Age 18 years to 70 years; women only (registered criteria)

    Led by West China HospitalChengdu

  624. Not yet recruiting
    Ultrasound Monitoring of Clipped Lymph Nodes to Predict Axillary Response After Chemotherapy in Breast Cancer
    Phase
    Not given
    Started
    2026-05
    Posted
    Registry
    NCT07596472

    Age 18 years to Not stated; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  625. Not yet recruiting
    Super-Resolution Ultrasound Imaging for Assessing Response to Neoadjuvant Chemotherapy in Breast Cancer
    Phase
    Not given
    Started
    2026-06
    Posted
    Registry
    NCT07623226

    Age 18 years to 75 years; women only (registered criteria)

    Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei

  626. Not yet recruiting
    A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07623642

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Harbin

  627. Not yet recruiting
    Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07628504

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  628. Not yet recruiting
    Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07630103

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  629. Not yet recruiting
    Molecular Subtype-Guided Postoperative Radiotherapy for Phyllodes Tumor of the Breast
    Phase
    N/A
    Started
    2026-10
    Posted
    Registry
    NCT07657169

    Age 18 years to 75 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 3 listed hospitals as study sitesGuangzhou, Jinan, Qingdao, Shenzhen

  630. Not yet recruiting
    Risk-Stratified Hypofractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer
    Phase
    N/A
    Started
    2026-06
    Posted
    Registry
    NCT07657442

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  631. Not yet recruiting
    A Phase II Study of Radiation Therapy to Treat Refractory Breast Cancer
    Phase
    N/A
    Started
    2026-06
    Posted
    Registry
    NCT07672743

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  632. Not yet recruiting
    Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2026-08
    Posted
    Registry
    NCT07684456

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  633. Not yet recruiting
    Research on AI Models for Predicting Breast Cancer Treatment Effectiveness to Guide Her-2 Targeted ADC Therapy
    Phase
    Not given
    Started
    2026-08
    Posted
    Registry
    NCT07689929

    Age not stated; women only (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  634. Not yet recruiting
    Kumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07691333

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fujian Cancer Hospital; 2 listed hospitals as study sitesFuzhou, Quanzhou

  635. Not yet recruiting
    Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07745257

    Age 18 years to 80 years; women only (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 8 listed hospitals as study sitesAnyang, Chengdu, Dalian, Guangzhou, Hangzhou, Nanchang, Nanjing, Shijiazhuang, Zhengzhou

  636. Not yet recruiting
    Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07752550

    Age 18 years to 100 years; women only (registered criteria)

    Led by Harbin Medical University Cancer HospitalHarbin

  637. Not yet recruiting
    A Comparative Study of Delayed Endoscopic DTI and Latissimus Dorsi ±Impalnt Reconstruction Post-Mastectomy
    Phase
    Not given
    Started
    2026-09
    Posted
    Registry
    NCT07757074

    Age 18 years to 70 years; women only (registered criteria)

    Led by West China HospitalChengdu

  638. Not yet recruiting
    Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07766772

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  639. Not yet recruiting
    Research on the Development and Validation of Personalized Exercise Prescription System for Breast Cancer Patients Based on Large Language Models
    Phase
    Not given
    Started
    2026-09
    Posted
    Registry
    NCT07767565

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  640. Not yet recruiting
    Romiplostim N01 for Injection for Secondary Prophylaxis of CIT in Breast Cancer
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07771881

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  641. Not yet recruiting
    A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer
    Phase
    N/A
    Started
    2026-09
    Posted
    Registry
    NCT07782086

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Hefei, Luzhou, Nanjing, Shanghai, Xi'an, Xuzhou

  642. Not yet recruiting
    SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07787338

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  643. Not yet recruiting
    SLNB Combined With WLNB for Axillary De-escalation in Breast Cancer Patients With Abnormal Axillary Nodes
    Phase
    Not given
    Started
    2026-07
    Posted
    Registry
    NCT07791771

    Age 18 years to Not stated; women only (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  644. Not yet recruiting
    Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07795424

    Age 18 years to 70 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical University; 1 listed hospital as study siteShenyang

  645. Not yet recruiting
    Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast Cancer
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07801898

    Age 18 years to 18 years (registered criteria)

    Led by Second Affiliated Hospital of Anhui Medical UniversityHefei

  646. Not yet recruiting
    Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07825753

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  647. Not yet recruiting
    A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXd
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07836257

    Age 18 years to Not stated (registered criteria)

    Led by Fujian Cancer HospitalFuzhou

  648. Not yet recruiting
    Chinese Herbal Acupoint Application Combined With Triple Antiemetic Therapy for Prevention of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07848984

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  649. Not yet recruiting
    Impact of Robotic Versus Endoscopic Surgery on Nipple Nerve Function Following Nipple-Sparing Mastectomy for Breast Cancer
    Phase
    N/A
    Started
    2026-10
    Posted
    Registry
    NCT07850154

    Age not stated (registered criteria)

    Led by Guangzhou Women and Children's Medical CenterGuangzhou

  650. Not yet recruiting
    SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07856303

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  651. Not yet recruiting
    A Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080
    Phase
    Phase 1
    Started
    2026-11
    Posted
    Registry
    NCT07876596

    Age 18 years to 55 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  652. Not yet recruiting
    Exploring Curative Model for Advanced Breast Cancer: a Single-center, Prospective Phase II Clinical Study
    Phase
    Not given
    Started
    2026-10
    Posted
    Registry
    NCT07888556

    Age not stated; women only (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  653. Not yet recruiting
    Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2026-11
    Posted
    Registry
    NCT07892274

    Age 18 years to 80 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  654. Not yet recruiting
    Adding Preoperative Radiotherapy Based on Early Treatment Response in Breast Cancer
    Phase
    Phase 2
    Started
    2026-11
    Posted
    Registry
    NCT07892508

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  655. Not yet recruiting
    A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2026-11
    Posted
    Registry
    NCT07894328

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  656. Not yet recruiting
    Albumin-Bound Paclitaxel (Ⅱ) in Patients With Advanced Breast Cancer
    Phase
    Not given
    Started
    2026-10
    Posted
    Registry
    NCT07899047

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  657. Not yet recruiting
    Study on the Construction and Implementation Effect of a Traditional Chinese Medicine-Based Mental-Physical Comorbidity Linked Health-Management System of "Hospital-Community-Family" for Breast Cancer Patients
    Phase
    N/A
    Started
    2026-10
    Posted
    Registry
    NCT07942103

    Age 18 years to 70 years; women only (registered criteria)

    Led by First Teaching Hospital, Tianjin University of Traditional Chinese MedicineTianjin

  658. Not yet recruiting
    Multimodal LLM for Breast Cancer Radiotherapy Target Auto-Contouring and Planning
    Phase
    Not given
    Started
    2026-11
    Posted
    Registry
    NCT07943494

    Age not stated (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  659. Not yet recruiting
    Randomized Controlled Clinical Study on the Reduction of Tumor Marker Levels in Breast Cancer Patients by Huaier Granules
    Phase
    Phase 4
    Started
    2025-09
    Posted
    Registry
    NCT05871437

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  660. Not yet recruiting
    Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT06556862

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  661. Not yet recruiting
    Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06797622

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  662. Not yet recruiting
    Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT06798506

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  663. Not yet recruiting
    This Study Aims to Explore the Efficacy of Hyperbaric Oxygen in the Treatment of Flap Ischaemic Necrosis After Breast Cancer Surgery
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT06811857

    Age 18 years to 60 years; women only (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  664. Not yet recruiting
    Hyperbaric Oxygen Therapy for Peripheral Neuropathy Due to Paclitaxel Analogs
    Phase
    N/A
    Started
    2025-02
    Posted
    Registry
    NCT06819501

    Age 18 years to 60 years; women only (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  665. Not yet recruiting
    A Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Hormone Receptor Positive Breast Cancer Patients
    Phase
    N/A
    Started
    2025-02
    Posted
    Registry
    NCT06825949

    Age 18 years to 60 years; women only (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  666. Not yet recruiting
    A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Triple-Negative and HER2+ Breast Cancer Patients
    Phase
    N/A
    Started
    2025-02
    Posted
    Registry
    NCT06825975

    Age 18 years to 60 years; women only (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  667. Not yet recruiting
    Familial Breast Cancer in China
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT06833216

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  668. Not yet recruiting
    Establishment and Clinical Application of Breast Cancer Risk Prediction Model Based on Traditional Chinese Medicine Four Diagnostic Instruments and Ultrasound
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT06902935

    Age 30 years to 75 years; women only (registered criteria)

    Led by Taizhou HospitalTaizhou

  669. Not yet recruiting
    The Efficacy of Oral Cryotherapy in Preventing TROP2-ADC-Induced Oral Mucositis in Patients With Advanced Breast Cancer
    Phase
    N/A
    Started
    2025-05
    Posted
    Registry
    NCT06934733

    Age 18 years to Not stated; women only (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  670. Not yet recruiting
    Patient Education Strategy for Breast Cancer Patients During Perioperative Hospitalization Stage
    Phase
    N/A
    Started
    2025-06
    Posted
    Registry
    NCT06965556

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  671. Not yet recruiting
    Clinical Application of PET Imaging Targeting Nectin-4 in Malignant Tumors
    Phase
    N/A
    Started
    2025-07
    Posted
    Registry
    NCT06994078

    Age 18 years to 65 years (registered criteria)

    Led by Union HospitalWuhan

  672. Not yet recruiting
    Acupuncture for Anxiety and Depression
    Phase
    N/A
    Started
    2025-05
    Posted
    Registry
    NCT06994351

    Age 18 years to 70 years; women only (registered criteria)

    Led by Guang'anmen HospitalBeijing

  673. Not yet recruiting
    Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06996093

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  674. Not yet recruiting
    Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07005583

    Age 18 years to 75 years; women only (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  675. Not yet recruiting
    EpCAM-Targeted Surface-Enhanced Raman Spectroscopy Nanotags for Rapid Evaluation of Surgical Margins and Sentinel Lymph Node Metastasis Status in Breast Cancers
    Phase
    Not given
    Started
    2025-06
    Posted
    Registry
    NCT07018505

    Age 18 years to 75 years; women only (registered criteria)

    Led by Yunnan Cancer HospitalKunming

  676. Not yet recruiting
    A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
    Phase
    Phase 1
    Started
    2025-06
    Posted
    Registry
    NCT07036185

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  677. Not yet recruiting
    A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07040644

    Age 18 years to Not stated; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  678. Not yet recruiting
    SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07047443

    Age 18 years to 75 years; women only (registered criteria)

    Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei

  679. Not yet recruiting
    A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07054242

    Age 18 years to 75 years (registered criteria)

    Led by Yantai Yuhuangding HospitalYantai

  680. Not yet recruiting
    Human-AI Collaborative INSIGHT Diagnostic Workflow for in Breast Cancer With Extensive Intraductal Component
    Phase
    N/A
    Started
    2025-08
    Posted
    Registry
    NCT07060599

    Age not stated; women only (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  681. Not yet recruiting
    Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07061717

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  682. Not yet recruiting
    Artificial Intelligence Model-Assisted Accurate Diagnosis of Early-Stage Breast Cancer
    Phase
    Not given
    Started
    2025-08
    Posted
    Registry
    NCT07063667

    Age 19 years to 85 years (registered criteria)

    Led by Daping Hospital, Army Medical UniversityChongqing

  683. Not yet recruiting
    Fasting-Mimicking Diet as an Adjunct to Neoadjuvant Chemotherapy for Hormone-Receptor-Positive Breast Cancer
    Phase
    N/A
    Started
    2025-07
    Posted
    Registry
    NCT07077018

    Age 18 years to 75 years (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  684. Not yet recruiting
    Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2025-07
    Posted
    Registry
    NCT07088588

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  685. Not yet recruiting
    Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer
    Phase
    Phase 4
    Started
    2025-08
    Posted
    Registry
    NCT07093931

    Age 18 years to 70 years; women only (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  686. Not yet recruiting
    QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07113964

    Age 18 years to 75 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  687. Not yet recruiting
    Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07136974

    Age 18 years to 70 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  688. Not yet recruiting
    Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07139470

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  689. Not yet recruiting
    De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07153757

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  690. Not yet recruiting
    Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07153965

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  691. Not yet recruiting
    Cohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast Cancer
    Phase
    Phase 4
    Started
    2025-10
    Posted
    Registry
    NCT07162259

    Age 18 years to 85 years; women only (registered criteria)

    Led by Xi'an International Medical Center HospitalXi'an

  692. Not yet recruiting
    A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors
    Phase
    Phase 1
    Started
    2025-10
    Posted
    Registry
    NCT07163481

    Age 18 years to Not stated (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  693. Not yet recruiting
    Simple Surgical Glove Compression to Prevent Chemotherapy-Induced Peripheral Neuropathy
    Phase
    N/A
    Started
    2025-09
    Posted
    Registry
    NCT07169864

    Age 18 years to Not stated (registered criteria)

    Led by Renji HospitalShanghai

  694. Not yet recruiting
    Acupuncture for Anxiety/Depression in Patients With Breast Cancer
    Phase
    N/A
    Started
    2025-09
    Posted
    Registry
    NCT07183813

    Age 18 years to 70 years; women only (registered criteria)

    Led by Guang'anmen HospitalBeijing

  695. Not yet recruiting
    Correlation Between COVID-19 and Radiation Pneumonitis in Breast Cancer
    Phase
    Not given
    Started
    2025-09
    Posted
    Registry
    NCT07188116

    Age 18 years to 80 years; women only (registered criteria)

    Led by Zhejiang Hospital; 1 listed hospital as study siteHangzhou

  696. Not yet recruiting
    Drain Removal on Postoperative Safety and Patient Satisfaction in R-E-NSM With Prepectoral DIBR
    Phase
    N/A
    Started
    2025-12
    Posted
    Registry
    NCT07237828

    Age 18 years to 70 years; women only (registered criteria)

    Led by West China HospitalChengdu

  697. Not yet recruiting
    Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07246317

    Age 18 years to 70 years; women only (registered criteria)

    Led by Tianjin Medical University Cancer Institute & Hospital; 4 listed hospitals as study sitesGuangzhou, Luoyang, Shijiazhuang, Tianjin

  698. Not yet recruiting
    Combined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07254858

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou

  699. Not yet recruiting
    A Nationwide Multicenter, Single-arm, Retrospective Study of Delayed Endoscopic DTI-BR After Simple Mastectomy
    Phase
    N/A
    Started
    2025-12
    Posted
    Registry
    NCT07257003

    Age 18 years to 70 years; women only (registered criteria)

    Led by West China HospitalChengdu

  700. Not yet recruiting
    RaSOLVE: 125I Radioactive Seed Marking Effects on Pathological Complete Response Rate and Prognosis Post-Neoadjuvant Therapy in Early/Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07269691

    Age 18 years to 70 years; women only (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  701. Not yet recruiting
    Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer
    Phase
    Phase 2
    Started
    2024-02
    Posted
    Registry
    NCT06202313

    Age 18 years to 75 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  702. Not yet recruiting
    Aerobic Dance During Chemotherapy in Breast Cancer Patients With Cognitive Impairment
    Phase
    N/A
    Started
    2024-04
    Posted
    Registry
    NCT06234150

    Age 18 years to 65 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  703. Not yet recruiting
    Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial
    Phase
    Phase 4
    Started
    2024-01
    Posted
    Registry
    NCT06245824

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  704. Not yet recruiting
    Myeloprotection With Trilaciclib in Pan-cancer Population
    Phase
    Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06297811

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  705. Not yet recruiting
    A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06354114

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHarbin

  706. Not yet recruiting
    Aromatherapy in the Treatment of Early Breast Cancer
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06435104

    Age 18 years to 80 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  707. Not yet recruiting
    Clinical Effectiveness of CEM in Diagnosis of Additional Findings at Preoperative Breast Magnetic Resonance Imaging
    Phase
    N/A
    Started
    2024-07
    Posted
    Registry
    NCT06475066

    Age 18 years to 75 years; women only (registered criteria)

    Led by Union HospitalWuhan

  708. Not yet recruiting
    Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06510465

    Age 18 years to Not stated (registered criteria)

    Led by Renji HospitalShanghai

  709. Not yet recruiting
    T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06548178

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  710. Not yet recruiting
    To Evaluate the Effectiveness and Safety of the Single-port Robotic-assisted Breast Surgery in Breast Cancer
    Phase
    N/A
    Started
    2024-08
    Posted
    Registry
    NCT06561646

    Age 18 years to 75 years; women only (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  711. Not yet recruiting
    A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
    Phase
    Phase 1
    Started
    2024-11
    Posted
    Registry
    NCT06614751

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing

  712. Not yet recruiting
    Comparing the Safety and Cosmetic Outcomes Between Laparoscopic Versus Traditional Open Breast-conserving Surgery
    Phase
    N/A
    Started
    2024-10
    Posted
    Registry
    NCT06671249

    Age 18 years to Not stated; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  713. Not yet recruiting
    A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06724263

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  714. Not yet recruiting
    JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06731153

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  715. Not yet recruiting
    Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06750848

    Age 18 years to 75 years (registered criteria)

    Led by Shantou University Medical College hospitalsShantou

  716. Not yet recruiting
    A Randomized Controlled Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined with Systemic Therapy for Early-stage Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2024-12
    Posted
    Registry
    NCT06769919

    Age 18 years to 65 years; women only (registered criteria)

    Led by Xijing HospitalXi'an

  717. Not yet recruiting
    Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
    Phase
    Phase 4
    Started
    2023-07
    Posted
    Registry
    NCT05841849

    Age 18 years to 70 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  718. Not yet recruiting
    Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis
    Phase
    Phase 4
    Started
    2023-10
    Posted
    Registry
    NCT05860907

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 6 listed hospitals as study sitesChangsha, Hangzhou, Shanghai, Shijiazhuang, Yangzhou, Zhengzhou

  719. Not yet recruiting
    Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT05979220

    Age 18 years to 75 years; women only (registered criteria)

    Led by West China HospitalChengdu

  720. Not yet recruiting
    Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT05983094

    Age 18 years to 70 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  721. Not yet recruiting
    Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis
    Phase
    N/A
    Started
    2023-09
    Posted
    Registry
    NCT06015113

    Age 18 years to Not stated; women only (registered criteria)

    Led by Xi'an International Medical Center HospitalXi'an

  722. Not yet recruiting
    The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
    Phase
    Phase 1/Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06140576

    Age 18 years to 70 years; women only (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  723. Not yet recruiting
    The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis
    Phase
    Phase 2
    Started
    2022-06
    Posted
    Registry
    NCT05431504

    Age 18 years to Not stated; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  724. Not yet recruiting
    Acupuncture for Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.
    Phase
    N/A
    Started
    2022-08
    Posted
    Registry
    NCT05460819

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing

  725. Not yet recruiting
    Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer
    Phase
    Early phase 1
    Started
    2022-10
    Posted
    Registry
    NCT05505812

    Age 18 years to 75 years; women only (registered criteria)

    Led by Affiliated Hospital of Qingdao UniversityQingdao

  726. Not yet recruiting
    Study of Acupuncture in the Treatment of Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.
    Phase
    N/A
    Started
    2022-12
    Posted
    Registry
    NCT05613504

    Age 30 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing

  727. Not yet recruiting
    Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
    Phase
    Phase 3
    Started
    2021-02
    Posted
    Registry
    NCT04736589

    Age 18 years to 85 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  728. Not yet recruiting
    Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy
    Phase
    Phase 3
    Started
    2021-08
    Posted
    Registry
    NCT04973319

    Age 18 years to 75 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  729. Not yet recruiting
    A Prospective Cohort Study Comparing Disparity in Surgical Procedure (Wide Local Excision Only vs Any Other Surgery Procedures) Among the Elderly Breast Cancer Patients
    Phase
    Not given
    Started
    2020-06
    Posted
    Registry
    NCT04426136

    Age 70 years to Not stated; women only (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  730. Enrolling by invitation
    Endoscopic Nipple-Sparing Mastectomy (E-NSM) With Immediate Multistage Autologous Fat Grafting(IMAFG) for Total Breast Reconstruction Via the Axillary Incision
    Phase
    N/A
    Started
    2026-01
    Posted
    Registry
    NCT07352137

    Age 18 years to 70 years; women only (registered criteria)

    Led by Guangdong Provincial Hospital of Chinese MedicineGuangzhou

  731. Enrolling by invitation
    Fertility Outcomes In Young Breast Cancer Patients And Their Prognosis And Offspring Health
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07376681

    Age 18 years to 40 years; women only (registered criteria)

    Led by Taizhou HospitalTaizhou

  732. Enrolling by invitation
    Influencing Factors and Mechanisms of Capsular Contracture After Prosthesis Reconstruction in Patients With Breast Cancer
    Phase
    Not given
    Started
    2026-03
    Posted
    Registry
    NCT07419971

    Age 18 years to 80 years; women only (registered criteria)

    Led by West China HospitalChengdu

  733. Enrolling by invitation
    Exercise Intervention for Breast Cancer Patients With Sarcopenia
    Phase
    N/A
    Started
    2026-09
    Posted
    Registry
    NCT07732101

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  734. Enrolling by invitation
    Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
    Phase
    Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06650748

    Age 18 years to 70 years; women only (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  735. Enrolling by invitation
    A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer
    Phase
    Not given
    Started
    2025-01
    Posted
    Registry
    NCT06791161

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  736. Enrolling by invitation
    A Study Comparing the Differences Between Young and Non-young Breast Cancer
    Phase
    Not given
    Started
    2025-01
    Posted
    Registry
    NCT06793306

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  737. Enrolling by invitation
    Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06843681

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  738. Enrolling by invitation
    Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer(UPGRADE-TNBC)
    Phase
    Phase 2/Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06910072

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  739. Enrolling by invitation
    Efficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment
    Phase
    Not given
    Started
    2025-05
    Posted
    Registry
    NCT06914661

    Age 18 years to 100 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  740. Enrolling by invitation
    Breast Cancer PET/CT Imaging With 68Ga-pAKTi
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT06943313

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  741. Enrolling by invitation
    PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors
    Phase
    Early phase 1
    Started
    2025-07
    Posted
    Registry
    NCT07023848

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Jiangnan UniversityWuxi

  742. Enrolling by invitation
    The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies
    Phase
    Early phase 1
    Started
    2025-07
    Posted
    Registry
    NCT07023861

    Age 15 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Jiangnan UniversityWuxi

  743. Enrolling by invitation
    A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07376629

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesAnyang, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanjing, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou

  744. Enrolling by invitation
    Impact of an Artificial Intelligence-Based Management Model on Psychological and Behavioral Outcomes in Breast Cancer Patients Undergoing Home CDK4/6 Inhibitor Therapy
    Phase
    N/A
    Started
    2025-07
    Posted
    Registry
    NCT07409298

    Age 18 years to 80 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  745. Enrolling by invitation
    Concept-verification Clinical Trial on the Inhibition of Breast Cancer Lung Metastasis Progression by Hyperbaric Oxygen
    Phase
    N/A
    Started
    2025-11
    Posted
    Registry
    NCT07514728

    Age 18 years to 75 years; women only (registered criteria)

    Led by Central Hospital Affiliated to Shandong First Medical UniversityJinan

  746. Enrolling by invitation
    Immediate Autologous Tissue Breast Reconstruction and Radiotherapy Strategy After Breast Cancer Surgery
    Phase
    Not given
    Started
    2025-09
    Posted
    Registry
    NCT07798466

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  747. Enrolling by invitation
    Effect of (neo)Adjuvant Therapy on Lipids in Young Breast Cancer Patients
    Phase
    Not given
    Started
    2024-05
    Posted
    Registry
    NCT06405269

    Age 18 years to 40 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  748. Enrolling by invitation
    Intensive Adjuvant Therapy for TNBC with BRCA Gene Mutation
    Phase
    Not given
    Started
    2024-05
    Posted
    Registry
    NCT06405295

    Age 18 years to 75 years; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  749. Enrolling by invitation
    Real-world Study on Shenbailing Granules for Improving Qi and Blood Deficiency in Patients After Breast Cancer Surgery
    Phase
    N/A
    Started
    2024-12
    Posted
    Registry
    NCT06881550

    Age 18 years to 75 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  750. Enrolling by invitation
    Radiotherapy with Immunotherapy and Anti-Angiogenic Therapy for Advanced HER2-Negative Breast Cancer: a Single-Arm Study
    Phase
    Phase 1/Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06890871

    Age 18 years to 75 years; women only (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

  751. Enrolling by invitation
    Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT07359404

    Age 18 years to Not stated; women only (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  752. Enrolling by invitation
    18F-FES PET/CT in the Treatment Planning, and Response Assessment of ER-Positive Breast Cancer
    Phase
    Not given
    Started
    2024-05
    Posted
    Registry
    NCT07859046

    Age 18 years to 80 years; women only (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  753. Enrolling by invitation
    Investigating the Effects of Different Incision Types on Aesthetic Outcomes and Incision-related Complications After Breast Reconstruction Surgery
    Phase
    Not given
    Started
    2023-07
    Posted
    Registry
    NCT06258863

    Age 18 years to Not stated; women only (registered criteria)

    Led by Hubei Cancer HospitalWuhan

  754. Enrolling by invitation
    T-DM1 Combined With CDK4/6 Inhibitor Ribociclib
    Phase
    Phase 2
    Started
    2023-10
    Posted
    Registry
    NCT06481956

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Additional research sources

Read the linked papers and reports

Where these numbers come from

Papers

16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search

Trials

ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 18 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data (CSV)Definitions